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                                                                                                                                 Introduction 
1. Introduction 
1.1. Pathophysiology of ischemia/reperfusion lung injury 
1.1.1. Definitions 
Cellular damage caused by restoration of blood supply to previously viable ischemic tissues 
is defined as ischemia/reperfusion (IR) injury. The consequences of depriving an organ of its 
blood supply (ischemia) have long been recognized as a critical factor in the clinical 
outcome of stroke, myocardial infarction and organ transplantation. Although restoration of 
circulation (reperfusion) is essential for the recovery of normal cellular function and 
prevention of irreversible tissue injury, reperfusion may itself initiate a series of 
pathophysiological alterations that can augment tissue injury in excess of that produced by 
ischemia alone. For example, it was demonstrated in a feline model of intestinal ischemia 
that 4 h of ischemia alone caused less severe injury than 3 h of ischemia followed by 1 h of 
reperfusion.1 
 
The absence of oxygen and nutrients from blood creates a condition in which the restoration 
of circulation results in inflammation and oxidative damage through the induction of 
oxidative stress rather than restoration of normal function. Tissue injury after reperfusion 
may have serious consequences depending on the organ, e.g., myocardial infarction or 
stunning, stroke, and injury after organ transplantation or cardiac bypass surgery. In the lung 
IR injury is characterized by impairment of gas exchange, increased microvascular 
permeability because of endothelial dysfunction and injury and ensuing pulmonary edema.2, 
3 Lung IR injury can adversely affect graft function in the early post-transplantation period, 
leading to primary graft failure with increased morbidity and mortality in transplant 
patients.4 Despite substantial advances in lung preservation and improvements in surgical 
techniques and perioperative care IR-induced lung injury remains an important cause of 
early morbidity and mortality in transplanted patients.5 In addition to significant morbidity 
and mortality in the early postoperative period severe IR injury can also be associated with 
an increased risk of acute rejection that can adversely affect graft function in the long term.6 
IR-induced injury may also occur in a variety of other clinical conditions, including 
reperfusion after thrombolytic therapy,7 pulmonary thromboendarterectomy,8, 9 myocardial 
infarction,10 cardiopulmonary bypass surgery,11, 12 severe circulatory shock,13 and stroke.14 
Because diseases due to ischemia (e.g., myocardial infarction and stroke) are exceedingly 
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common causes of morbidity and mortality in the population and because organ 
transplantation has had increasing success and has become the mainstay of therapy for most 
end-stage diseases, understanding the pathomechanisms of IR injury has the potential to lead 
to therapies that could improve public health. 
 
1.1.2. Organ ischemia 
Oxygen as a basic fuel is essential to cell function. Interruption of the blood supply to a 
tissue initiates a sequence of events leading to cellular dysfunction and death. The severity 
of ischemic injury is determined by both the duration and the extent of blood flow decrease 
to an organ or tissue.15 During ischemia, an inadequate supply of O2 leads to a cessation in 
adenosine triphosphate (ATP) synthesis and the cell is deprived of the energy needed to 
maintain homeostasis. Anaerobic metabolism becomes the main source of ATP production. 
Decreased ATP inactivates the ATP-dependent cell membrane pumps resulting in even 
greater cellular dysfunction. Inefficient removal of waste products may eventually lead to 
increased local accumulation of lactic acid. The resulting acidosis alters normal enzyme 
kinetics. Furthermore, the activation of nuclear factor-kB during ischemia initiates 
inflammatory reactions. Increased expression of adhesion molecules favours augmented 
polymorphonuclear leukocytes adhesion at the site of IR injury during reperfusion. 
 
1.1.3. Reperfusion of the ischemic organ 
Reperfusion is an absolute prerequisite for cellular salvage and recovery from ischemic 
injury as re-establishing blood flow leads to restoration of the energy supply and removal of 
waste products. However, reperfusion itself may lead to additional tissue injury beyond that 
generated by ischemia alone, thus representing the “double edged sword”.16 On reperfusion, 
reintroduction of abundant oxygen at the onset of reperfusion evokes within the first few 
minutes of reflow a burst of potent reactive oxygen species (ROS). Activation and 
accumulation of leukocytes in the tissue result in release of ROS, proteases, cytotoxic and 
chemotactic substances, that further amplify the infiltration of neutrophils. Longer periods of 
ischemia can lead to physical obstruction of capillaries, the so called no-reflow 
phenomenon. Cellular edema may also cause capillary plugging during reperfusion thus 
contributing to this phenomenon. A rise in pulmonary artery pressure is frequently seen after 
reperfusion, in both lung transplantation recipients17 and animal models18-20 This rise in 
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hydrostatic force may further increase extravascular accumulation of protein in the lung 
interstitium during reperfusion. 
 
1.1.4. Leukocytes and ischemia/reperfusion 
A deleterious role for circulating polymorphonuclear leukocytes in lung IR has been inferred 
from the protective effect of polymorphonuclear leukocyte depletion21 and reduced injury 
following adhesion molecule inhibition,22-25. After ischemia, local tissue reperfusion 
generates a number of inflammatory mediators that attract circulating leukocytes. Cell 
adhesion molecules on the leukocyte surface bind to ligands on endothelial cells, initiating a 
sequence of events resulting in extravasation of leukocytes from the microvasculature. 
Activated neutrophils can cause tissue injury via ROS generation during the respiratory 
burst.26 They also release potent proteolytic enzymes capable of degrading almost all 
components of the endothelial basement membrane as well as junctional proteins that 
maintain endothelial barrier function.27 In addition, progressive microcirculatory obstruction 
by leukocytes in the microcirculation underlying the no-reflow phenomenon may limit 
adequate perfusion after reperfusion. Thus, a vicious cycle occurs during reperfusion, with 
continued neutrophil chemotaxis and activation leading to additional ROS formation, 
endothelial damage, and capillary plugging. 
 
Although many investigations have confirmed the role of neutrophils in reperfusion injury, 
others have questioned neutrophil involvement. Deeb and colleagues demonstrated that 
neutrophils are not necessary to induce reperfusion injury in a rat lung preparation using 
isolated blood cell components.28 Neutrophil-independent reperfusion injury using anti-rat 
neutrophil antibodies was also demonstrated in an in vivo rat lung model at 90 minutes of 
reperfusion.29 Their study demonstrated that the injury was not associated with 
polymorphonuclear leukocyte sequestration. Eppinger et al30 in a similar in vivo study found 
that during lung IR, there is a bimodal pattern of injury, consisting of both neutrophil-
independent and neutrophil-mediated events. These findings suggest neutrophil involvement 
in reperfusion injury occurs during the late phase of reperfusion and that other cells are 
responsible for the earliest phase of reperfusion injury. As early injury occurs well before 
significant tissue neutrophil infiltration has occurred, it is likely dependent on a resident cell 
type such as the alveolar macrophage. However, the role of resident lung leukocytes in lung 
IR injury remains controversial. 
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Pulmonary macrophages consist of different sub-populations, i.e., alveolar macrophages as 
well as interstitial, pleural, and vascular macrophages.31 Vascular macrophages exist in the 
sheep, the calf, and the goat, but not in rodents.31 Alveolar macrophages comprise the 
majority of pulmonary resident leukocytes in rodents.32 Although, alveolar macrophages 
play a crucial role in the defence system of the lung, they also can induce damage to the 
lung.33, 34 Activated macrophages can contribute the pathogenesis of tissue injury by 
releasing an array of mediators, including proinflammatory and cytotoxic cytokines, 
bioactive lipids, hydrolytic enzymes, ROS, and nitric oxide. Inhibition of macrophage 
function with gadolinium chloride 35-37 as well as depletion of alveolar macrophages by 
clodronate liposomes protects lungs from IR-induced injury.38, 39 In contrast, Nakamura et al 
40 demonstrated that intratracheal administration of liposome-encapsulated clodronate does 
not benefit, but aggravates, warm ischemia-reperfusion injury of the lung. 
 
 
1.1.5. Endothelial cells and ischemia/reperfusion 
The endothelium is strategically located at the interface between the wall of blood vessels 
and the blood stream and is “not just a cellophane wrapper”.41 The endothelial lining of 
blood vessels is an active tissue that plays a pivotal role in maintaining vascular 
homeostasis. Endothelial cells sense mechanical stimuli, ambient PO2, and hormonal stimuli 
and respond with appropriate changes in function to maintain homeostasis. They exert 
significant autocrine, paracrine and endocrine actions and regulate vasomotor function and 
tissue perfusion.42 Endothelial cells also modify the inflammatory processes by regulating 
the expression of the adhesion molecules that bind to neutrophil integrins and mediate 
neutrophil infiltration.43 The endothelium also plays a significant role in the regulation of 
hemostasis.43 
 
The increased generation of ROS during reperfusion after ischemia contributes to tissue 
injury, microvascular dysfunction, increased endothelial permeability, and endothelial 
“stunning”.44 Endothelial activation may serve to further enhance ROS production through 
the recruitment and activation of leukocytes. 
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1.2. Evaluation of lung injury in isolated lungs 
Normal pulmonary function and tissue integrity depend on the maintenance of fluid balance. 
Lung injury can be applied to conditions ranging from mild interstitial edema without tissue 
injury to massive and fatal destruction of the lung. Accumulation of pulmonary edema can 
result either from increased vascular filtration pressure or increased permeability of the 
pulmonary microvascular endothelial barrier. The methodologies employed for lung injury 
assessment range from non-specific measurement of edema formation to techniques for 
calculating values of specific permeability coefficient for the microvascular membrane in 
pulmonary vessels. Additionally, microscopic techniques can provide qualitative verification 
of lung injury and/or hydrostatic edema but are less useful for evaluating global lung 
dysfunction.45 
 
1.2.1. Measurement of pulmonary edema 
Formation of pulmonary edema can be quantitatively assessed using gravimetric techniques. 
There are four methods commonly applied in in vivo experiments: the lung wet weight, the 
lung wet weight/body weight ratio, the lung wet/dry weight ratio, and the extravascular lung 
water.45 In isolated perfused lung preparations lung weight can be monitored throughout 
experiment using a strain gauge force transducer. However, quantification of accumulated 
fluid alone does not allow discrimination between hydrostatic and permeability edema. 
 
1.2.2. Permeability measurements 
A variety of techniques for assessment of lung vascular permeability may be applied to 
isolated perfused lung preparations. Most are based on the extravascular escape of indicated 
molecules or the measurement of transvascular fluid filtration under conditions of 
hydrostatic challenge.46 
 
The determination of the capillary filtration coefficient (Kfc) is the most commonly used 
method for quantifying the lung microvascular barrier that has been used in numerous 
studies in isolated perfused lung preparations. Kfc characterizes the microvascular hydraulic 
conductivity and can be measured by gravimetric, indicator hemoconcentration, or tracer 
methods.47 The gravimetric method involves establishing a sustained step increase of the 
venous pressure to induce steady gain of lung weight. Gravimetric Kfc is calculated as the 
ratio of the rate of lung weight gain to the induced pressure increase. Kfc only increases with 
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lung injury and do not change with time, blood flow, and high microvascular pressures.48 
These measurements can be repeated several times over 1-6 h, allowing paired statistical 
comparisons of baseline and experimental states.45 
 
After an isogravimetric state is obtained, venous pressure is elevated. The increase of lung 
weight demonstrates two distinct components: 1) a rapid component caused by fluid volume 
shifting into the pulmonary vascular system, and 2) a slow component that is due to fluid 
filtering across the pulmonary exchange vessels into the interstitial spaces. Weight gain is 
determined by drawing a tangent to the weight gain curve over each 1-min interval. The rate 
of lung weight gain can be estimated by logarithmic extrapolation to time zero, curve fitting, 
or measuring the weight gain slope at some time after the microvascular pressure increase.45 
In the time zero extrapolation method, these weight gain values are then plotted as a 
semilogarithmic function of time after the vascular pressure increase. By use of this method, 
the first 2 min of the curve are considered to represent vascular volume changes, whereas 
the slow increase in weight gain between 2 and 8 min represents transcapillary fluid 
movement. A least-squares line that best fit the natural log of slow weight gain between 2 
and 8 min is extrapolated back to time 0 to determine the rate of fluid movement before any 
change in transcapillary Starling forces. Kfc values are normalized to 100 g initial lung wet 
weight and expressed as cm3 per minute per mm Hg per 100 g by assuming that 1 g weight 
is equivalent to 1 ml of filtered fluid. 
 
In our study the filtration coefficient is expressed in terms of the elevation of venous 
pressure. However, on sudden venous pressure elevation the resultant increase in capillary 
hydrostatic pressure is smaller than the change in venous pressure. This will result in some 
underestimation of the absolute magnitude of Kfc. The maximum possible variation is, 
however, smaller than 100%, because about half of the imposed venous pressure rise was 
measured to be even transmitted to the pulmonary artery.49 Another methodological 
difficulty in measuring Kfc is inherent in all gravimetric approaches. An accurate estimate 
of gravimetric Kfc values requires differentiation of the weight gain due to intravascular 
volume changes from that due to transcapillary filtration. The intravascular volume increase 
is complete by 2 min after an increase in microvascular pressure and then weight gain 
increases at a decreasing rate.50 A logarithmic extrapolation of the weight gain curve to time 
0 to obviate the influence of tissue Starling forces readjustment has been recommended.51 In 
contrary, Hancock et al. reported that the slow weight gain represents slow vascular volume 
changes that persists for about 20 min after a microvascular pressure increase.52 Therefore, 
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Parker et al.53 emphasize the necessity of maintaining the increased weight transient for 18–
20 min to minimize errors due to vascular stress relaxation during baseline Kfc 
measurements and completely separate the vascular volume and filtration components of 
lung weight gain. Parker et al.48 compared pulmonary Kfc values using measurements of 
transcapillary filtration rates based on laser densitometry and gravimetric measurement in 
isolated dog lungs. The authors found that Kfc values calculated by time zero extrapolation 
method were significantly higher than all other gravimetric or densitometric Kfc values. 
They concluded that small increases in Kfc may be obscured with use of the time zero 
extrapolation technique because of vascular stress relaxation persisting >3 min. However, in 
our models of pulmonary IR-induced injury lung vascular damage is so severe that the 
filtration component is considerably larger compared with the vascular volume component 
of lung weight gain, and therefore filtration rates can be measured using much shorter 
periods of weight gain.53 
 
 
1.3. Oxidative stress in lung ischemia/reperfusion 
Oxidative stress is characterized by an imbalance between prooxidants and antioxidants as a 
result of ROS overproduction that overwhelms the cellular antioxidant capacity.54 Under 
physiological conditions, ROS are produced in a controlled manner at low concentrations 
and the rate of their production is balanced by the rate of elimination. However, under 
pathological conditions, excessive ROS production and an imbalance between ROS 
formation and the diminished ability to scavenge them by antioxidants results in increased 
bioavailability of ROS.55-57 Increased levels of ROS cause oxidative damage of 
macromolecules, membranes, and DNA. Increased oxidative stress plays an important role 
in the pathophysiology of many diseases, including hypertension, atherosclerosis, diabetes, 
and ischemia/reperfusion.18, 58 
 
Ischemia/reperfusion injury has been extensively studied in various organ systems, including 
intestines, kidney, liver, and heart.59, 60 Much of this work suggests that ROS play a role in 
reperfusion injury59 The increased generation of ROS during reperfusion contributes to 
tissue injury, microvascular dysfunction, increased endothelial permeability. Numerous 
experimental studies have demonstrated the therapeutic potential of antioxidant treatment in 
preventing or treating primary graft dysfunction after lung transplantation;61 however, all 
clinical reports on the use of antioxidants are either case reports or case series. Thus, the role 
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of antioxidants in the treatment of primary graft dysfunction remains uncertain.62 However, 
clinical trials of oral supplementation with antioxidant vitamins for the prevention of 
cardiovascular events in patients at risk for cardiovascular disease have generally been 
unsuccessful,63, 64 suggesting that a therapeutic approach based on nonspecific ROS 
scavenging might be inappropriate. Selective inhibition of specific ROS-generating enzymes 
is another approach for reducing oxidative stress−induced tissue injury, although the exact 
molecular targets in lung IR have not yet been clearly defined. 
 
1.3.1. Oxidative stress and biology of reactive oxygen species 
ROS are formed as intermediates in reduction-oxidation processes.65 Superoxide anion is a 
precursor for other ROS generated in cells. Its production usually involves a one-electron 
reduction of molecular O2. Superoxide has an unpaired electron, which imparts high 
reactivity and renders it unstable and short-lived. Superoxide is poorly cell membrane 
permeable, but can cross cell membranes via anion channels.66 It can undergo several 
chemical reactions depending on the amount generated and the localization and proximity to 
other radicals and enzymes. Superoxide acts as an oxidizing agent, where it is reduced to 
hydrogen peroxide.65, 67 However, in pathological conditions, when produced in excess, it 
acts as a reducing agent and a significant amount of superoxide reacts with NO to produce a 
potentially deleterious peroxynitrite, also resulting in NO inactivation.67 
 
Dismutation of superoxide by SOD produces the much more stable ROS, hydrogen 
peroxide.65 Hydrogen peroxide is lipid soluble and crosses cell membranes. Hydrogen 
peroxide is then converted enzymatically into H2O by catalase and glutathione peroxidise.66 
The interaction of hydrogen peroxide and superoxide in the presence of transition metal-
containing molecules can yield the hydroxyl radical (Haber-Weiss reaction).65 These 
reactions are often involved in oxidative stress-associated tissue injury. The hydroxyl radical 
is the one of the most deleterious and potent oxidizing agents known. 
 
1.3.2. NADPH oxidases in ischemia/reperfusion 
ROS can be detected during both ischemia68 and reperfusion18 and are believed to play a 
central role in IR injury. The ability of superoxide dismutase (SOD) to attenuate 
experimental IR lung injury suggests that superoxide anion is a key ROS in this process.69 A 
major source of superoxide anion is the NADPH-dependent oxidase present in the plasma 
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membrane of PMN leukocytes.70 Although there are many other enzyme systems that can 
potentially produce superoxide anion in the lung, including the uncoupled NO synthase, 
xanthine oxidase, cytochrome P450, and mitochondrial respiratory chain enzymes, the 
contribution of these enzymes to vascular generation of ROS is relatively minor compared 
with NADPH oxidase.71 In addition, NADPH oxidase−derived ROS may promote and 
modulate oxygen radical production by other enzymes, thereby amplifying the total level of 
ROS.58 
 
Though an NADPH oxidase plays important physiological roles in phagocytes it can also 
contribute to the pathogenesis of many inflammatory diseases.72 Moreover, it has recently 
been shown that all vascular cell types (endothelial cells, vascular smooth muscle cells, and 
adventitial fibroblasts) produce ROS,73, 74 primarily via NADPH oxidase.55, 75, 76 A 
phagocyte-type NADPH oxidase expressed by endothelial cells is a predominant contributor 
to overall vascular ROS production; it has a specific critical role in vascular oxidative 
stress.77 Furthermore, vascular NADPH oxidase−derived superoxide has been implicated in 
the pathophysiology of many cardiovascular diseases, including atherosclerosis, 
hypertension, diabetic vasculopathy and heart failure.43 
 
Table 1. Tissue distribution of Nox enzymes. From Bedard and Krause, Physiol. Rev. 
2007;87:245-313,78 with modifications. 
 High-Level Expression Intermediate- to Low-Level Expression 
Nox1 Colon Smooth muscle, endothelium, uterus, placenta, 
prostate, osteoclasts, retinal pericytes 
Nox2 Phagocytes B lymphocytes, neurons, cardiomyocytes, skeletal 
muscle, hepatocytes, endothelium, hematopoietic 
stem cells, smooth muscle 
Nox3 Inner ear Fetal kidney, fetal spleen, skull bone, brain 
Nox4 Kidney, blood vessels Osteoclasts, endothelium, smooth muscle, 
hematopoietic stem cells, fibroblasts, keratinocytes, 
melanoma cells, neurons 
Nox5 Lymphoid tissue, testis Endothelium, smooth muscle, pancreas, placenta, 
ovary, uterus, stomach, various fetal tissues 
Duox1 Thyroid Airway epithelia, tongue epithelium, cerebellum, 
testis 
Duox2 Thyroid Salivary and rectal glands, gastrointestinal epithelia, 
airway epithelia, uterus, gall bladder, pancreatic 
islets 
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1.3.2.1. The NADPH oxidase family 
The classical NADPH oxidase was first described and characterized in phagocytes, and it 
was originally thought that this system was restricted only to phagocytes and used solely in 
host defence. However, recently several isoforms of phagocytic NADPH oxidase, each 
encoded for by separate genes and termed Noxs, have been identified in nonphagocytic 
cells.78 To date, the Nox family comprises five members (Nox1-5), of which Nox2 is 
gp91phox or the phagocytic isoform. All Nox family members are transmembrane proteins 
that transport electrons across biological membranes to reduce oxygen to superoxide. In 
accordance with this preserved function, there are some conserved structural properties of 
Nox enzymes that are common to all family members. 
 
1.3.2.2. Phagocytic NADPH oxidase 
The phagocytic NADPH oxidase plays a crucial role in nonspecific host defence against 
pathogens by generating large amounts of superoxide during the so-called respiratory burst. 
The complex consists of a membrane-integrated heterodimeric flavoprotein cytochrome 
b558, which is itself composed of 2 subunits (gp91phox and p22phox) and 4 or more cytosolic 
proteins (p47phox, p67phox, p40phox and a small regulatory protein GTPase Rac).55 
 
 
 
Figure 1. Activation of ROS generation by assembly of Phox regulatory proteins in 
phagocytes. From Lambeth, Nat Rev Immunol, 2004;4(3):181-979 with modifications. 
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Cytochrome b558 is considered to be the most important component of the complex with 
respect to both enzymatic stability and activity. In resting neutrophils, the NADPH oxidase 
is inactive but can be rapidly activated by various receptor-dependent and -independent 
stimuli (Fig. 1). Phosphorylation of p47phox upon cell stimulation leads to a conformational 
change allowing its interaction with p22phox.79 The cytosolic subunits form a complex that 
then migrates to the membrane, where it associates with the cytochrome b558 to assemble to 
an active form. Once assembled, the complex is active and generates superoxide by 
transferring an electron from cytoplasmic NADPH to extracellular or phagosomal oxygen to 
generate superoxide. 
 
1.3.2.3. Endothelial NADPH oxidase 
It is now well recognized that endothelial cells constitutively express a superoxide-
generating enzyme analogous to the phagocytic NADPH oxidase of neutrophils. Several 
studies have suggested that, at a molecular level, the endothelial NADPH oxidase is similar 
to the phagocyte NADPH oxidase complex in that all the classical phagocytic oxidase 
subunits are expressed in endothelial cells.75 Despite this similarity at a molecular level, 
there are significant functional differences between the phagocytic and endothelial NADPH 
oxidase. In particular, in contrast to the phagocytic enzyme, the endothelial oxidase is pre-
assembled and constitutively active at a low level even in unstimulated cells, although its 
activity can be further increased by agonists.80 Furthermore, it never generates a level of 
ROS comparable to the high burst activity of the phagocytic enzyme. Endothelial NADPH 
oxidase is regulated by many humoral factors, including cytokines, growth factors and 
vasoactive agents.81 Physical factors, such as stretch, pulsatile strain and shear stress, also 
stimulate NADPH oxidase.44 
 
1.3.3. Inhibitors of NADPH oxidase 
The most commonly used NADPH oxidase inhibitor the iodonium-derivative diphenylene 
iodonium (DPI) represents a class of inhibitors of flavoprotein dehydrogenases that reduce 
activities of NADPH-dependent oxidase in the neutrophil and macrophage.82, 83 The 
compound acts by abstracting an electron from an electron transporter and forming a radical, 
which then inhibits the respective electron transporter through a covalent binding step.84 
However, as suggested by the mechanism of action, DPI is a nonspecific inhibitor of all 
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flavoenzymes, including NO synthase,85 xanthine oxidase,86 mitochondrial complex I,87 and 
others.88. 
 
4-(2-Aminoethyl)benzenesulfonylfluoride (AEBSF) is an irreversible serine protease 
inhibitor that inhibits NADPH oxidases by interfering with the association of the 
cytoplasmic subunit p47phox.89 It is not clear whether AEBSF really inhibits Nox enzymes or 
rather acts on signalling steps towards p47phox activation. AEBSF is also likely to have Nox-
unrelated effects due to serine protease inhibition.90 This mechanistic non-specificity and 
very weak potency of AEBSF make it unsuitable as a specific NADPH oxidase inhibitor.91 
 
Several peptide-based inhibitors of NADPH oxidases have been reported. The peptide 
inhibitor gp91ds-tat was designed specifically to inhibit Nox2 by mimicking a sequence of 
Nox2 that is thought to be important for the interaction with p47phox.92 The ds-tat sequence 
allows for binding and membrane transport of the peptide into the cell. However, the peptide 
is a low-efficacy inhibitor, inhibiting neutrophil ROS generation by 25% at 50 µM.92 
Another peptide-based inhibitor of NADPH oxidases, PR-39, is an endogenous proline-
arginine-rich antibacterial peptide secreted by neutrophils.93 The peptide inhibits the 
phagocyte NADPH oxidase by preventing association of the p47phox regulatory subunit 
with p22phox.93 However, PR-39 possesses antiadhesive properties by influencing some 
constitutive mechanisms involved in neutrophil trafficking,94 and therefore can attenuate IR 
injury independently of inhibition of NADPH oxidase. In addition, PR-39 alters mammalian 
cell gene expression and behaviour.95 
 
Apocynin (4-hydroxy-3-methoxy-acetophenone) is a naturally occurring methoxy-
substituted catechol derived from the root extract of the medicinal herb Picrorhiza kurroa.96 
Picrorhiza kurroa has been used as a herbal medicine for centuries to treat inflammation and 
certain infectious diseases.96 Apocynin has been shown to be a powerful anti-oxidant and 
anti-inflammatory agent in models of rheumatoid arthritis, inflammatory bowel disease, 
ischemic reperfusion lung injury, and respiratory muscle dysfunction in sepsis. The 
protective effects of apocynin are attributed to its ability to interfere with the assembly of 
enzyme subunits to form an active complex thereby preventing ROS generation.97 This 
mechanism was also demonstrated in endothelial cells.98 Apocynin has been used as an 
inhibitor of NADPH oxidases, both in neutrophils97 and in endothelial cells.99 It has recently 
been suggested that in non-phagocytic cells apocynin acts by functioning as a ROS 
scavenger, rather than an NADPH oxidase inhibitor and that it is therefore inappropriate to 
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use apocynin as a NADPH oxidase inhibitor in cells other than phagocytes.100 The findings 
of Heumueller et al100 question the results of many investigations showing the role of 
vascular NADPH oxidase as a major source of vascular ROS and oxidative stress. However, 
these conclusions were based on data derived from numerous studies that used various 
strategies to demonstrate the role of vascular NADPH oxidase.101 Therefore, apocynin is 
now used indiscriminately as a valid Nox inhibitor. 
 
1.3.4. Electron spin resonance spectroscopy 
Establishing the precise role of ROS in normal physiological processes and in the 
development of diseases requires the ability to measure them and the oxidative damage that 
they cause. Numerous methods have been developed for their detection. The currently 
available methods include chemiluminescence techniques, fluorescence-based assays, 
enzymatic assays, and electron spin resonance (ESR) spectroscopy. Among these methods, 
ESR spectroscopy is a unique technique for detecting ROS in various systems, providing the 
most direct and specific measurement. 
 
ESR spectroscopy is a technique for studying molecules that have one or more unpaired 
electrons, such as organic and inorganic free radicals or inorganic complexes possessing a 
transition metal ion. It deals with the interaction of electromagnetic radiation with the 
intrinsic magnetic moment of electrons arising from their spin. ESR detects the absorption 
of microwave energy, which occurs on transition of unpaired electrons in an applied 
magnetic field. The amplitude of the ESR signal is proportional to the number of the 
unpaired electrons present in the sample, allowing quantification of free radicals. 
 
Most of the biologically relevant radicals are present in extremely low concentration and 
very short-lived, so it is difficult to directly detect them by ESR in biological samples. 
Therefore, for ROS measurement by ESR diamagnetic radical scavengers or spin traps have 
been used. These spin traps incorporate the radical into their structure, forming a long-lived 
paramagnetic adducts with specific ESR spectra. These products can accumulate to levels 
permitting detection by ESR spectroscopy. Spin traps can be used to both identify and 
quantify the original ROS. The most popular spin traps are the nitrone compounds such as 
DEPMPO and DMPO. Unfortunately, nitrone spin traps have a very low efficacy for 
trapping of superoxide radicals.102 Furthermore, nitrone radical adducts are very susceptible 
to biodegradation and bioreduction to ESR silent species when exposed to biological 
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samples.102 For this reason, it is impossible to accurately quantify radicals formed in 
biological systems using the currently available nitrone spin traps. 
 
Recently, cyclic hydroxylamines were found to be effective scavengers of superoxide 
radicals.103 In contrast to nitrone spin traps, they are effective scavengers of superoxide and 
produce a stable nitroxide radical.104 Cyclic hydroxylamines, such as CPH or CMH, allow 
quantitative measurements of superoxide radicals with higher sensitivity than nitrone spin 
traps. Because these compounds can be oxidized by several ROS, it is necessary to perform 
paired experiments where SOD, a peroxynitrite scavenger, or other scavengers are added to 
define the ROS causing the reaction. 
 
 
+ O2•
_ 3.2x103 M-1s-1
+ H2O2
CP-H CP •
 
 
Figure 2. Reaction of CPH with superoxide. Oxidation of CPH forms the nitroxide CP• 
radical. The reactions of cyclic hydroxylamines with O2•- are hundred times faster than those 
with nitrone spin traps, thereby enabling the hydroxylamines to compete with cellular 
antioxidants and react with intracellular O2•-. 
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1.4. Aim of the study 
 
Pulmonary IR results in endothelial damage and dysfunction leading to the development of 
high permeability pulmonary edema. A "burst" of ROS in the first several minutes of 
reperfusion has been observed by many investigators.105 The first few minutes of reperfusion 
represent a critical phase because further tissue injury may be initiated at this time and most 
cell death occurs during reperfusion. Accordingly, therapeutic interventions must not only 
target specific cellular and molecular sources of ROS but also be delivered at precisely the 
right time. Thus, the present study aimed to investigate the role of phagocyte-type NADPH 
oxidase in the early phase of reperfusion. The relative contribution of NADPH oxidase 
expressed by resident leukocytes versus that from endothelial cells to IR-induced lung injury 
was also assessed. 
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2. Experimental protocols 
Inclusion criteria for the study were 1) a homogeneous white appearance of the isolated 
lungs with no signs of edema, hemostasis, or atelectasis; 2) initial pulmonary arterial (Ppa) 
and ventilation pressure values in the normal range; and 3) constancy of organ weight during 
an initial steady-state period of at least 20 min. 
 
 
2.1. Ischemia/reperfusion protocols 
 
2.1.1 Isolated lung preparations 
After termination of the initial steady-state period and a control hydrostatic challenge for 
assessment of baseline vascular permeability, the lungs were exposed to ischemia for 240 
min (rabbits) or 90 min (mice) by stopping the perfusion. The arterial and venous parts of 
the perfusion tubing were both clamped to maintain a positive intravascular pressure. During 
ischemia, the lungs were continuously ventilated with an anoxic gas mixture (95% N2, 5% 
CO2; Air Liquide, Deutschland GmbH, Ludwigshafen, Germany). At the end of the 
ischemic period, ventilation was returned to normoxia (21% O2, 5% CO2, 74% N2; Air 
Liquide), and perfusion was re-established by increasing the flow stepwise over 3 min. 
Hydrostatic challenges were repeated 30, 60, and 90 min after the onset of reperfusion. 
 
2.1.2. In vivo ischemia-reperfusion 
After a left anterolateral thoracotomy, the pulmonary hilum of the left lung was occluded for 
90 minutes using a noncrushing microsurgical clamp to create lung ischemia under the left 
lung in an inflated state. With removal of the clamp, the left lung was reperfused and 
reventilated for 90 minutes. Time-matched sham-operated WT and Nox2 KO animals served 
as controls. At the end of the reperfusion period, animals were sacrificed, and the left lungs 
were excised for assessment of tissue water content. 
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Figure 3. Representative original tracings of the isolated perfused mouse lung experiment. 
Typical tracings of pulmonary artery pressure, left ventricular pressure and weight changes 
in mouse lung reperfused after 90 min of lung ischemia induced by stopping perfusion. 
 
 
 
2.2. Measurements of vascular permeability and lung weight gain 
After termination of initial steady-state period a control hydrostatic challenge was 
performed, followed by anoxic ischemia. Hydrostatic challenges were then repeated 30, 60, 
and 90 min after the onset of reperfusion. 
 
Rabbit experimental groups included untreated lungs and lungs treated with a NADPH 
oxidase inhibitor, apocynin (500 μmol/L; Sigma-Aldrich, Steinheim, Germany) or 
superoxide dismutase (SOD; 150 U/mL; Sigma-Aldrich) which were admixed to the 
perfusion buffer shortly before the onset of anoxic ischemia. In nonischemic control group 
untreated lungs were continuously perfused and normoxically ventilated throughout the 
experiment, and hydrostatic challenges were performed at time points corresponding to IR 
experiments. 
 
Mouse experimental groups included lungs from wild-type (WT), Nox2 knockout (KO) and 
chimeric mice. Where indicated, an NADPH oxidase inhibitor, apocynin (500 μmol/L) or 
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SOD (150 U/mL) was admixed to the perfusion buffer of WT mouse lungs shortly before 
the onset of anoxic ischemia. In the time-matched non-ischemic control group, untreated 
lungs from WT mice were continuously perfused and normoxically ventilated throughout 
the experiment, and hydrostatic challenges were performed at time points corresponding to 
IR experiments. 
 
 
2.3. Measurements of ROS production 
In these experiments hand-made Teflon® cannulas were used in order to minimize 
contamination with transition metals of the perfusion buffer. After an initial steady state-
period mouse lungs were exposed to anoxic ischemia. The spin probe, CPH (1 mmol/L in 
rabbit experiments and 0.5 mmol/L in mouse experiments), was added into the perfusate at 
the end of ischemic period 5 min before the onset of reperfusion. Samples from the venous 
outflow of the isolated lung were collected in 50-µL glass capillary tubes and measured 
immediately at room temperature. Samples were collected every 15 sec during the first 3 
min of reperfusion and then every 1 min, or 5 min, as appropriate. Experimental groups 
included rabbit lungs and lungs from WT, Nox2 KO and chimeric mice. The contribution of 
superoxide radical to the formation of CP• was determined in separate experiments 
performed in the presence of SOD in the buffer fluid (150 U/mL). In time-matched non-
ischemic control lungs the spin probe was added, and perfusate samples were taken at time 
points corresponding to IR experiments. 
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3. Materials 
3.1. Chemicals, injecting solutions and drugs 
Isoflurane Abbott, Wiesbach, Germany 
Pentobarbital sodium (Narcoren) Merial GmbH, Hallbergmoos, Germany 
Heparin Rathiopharm GmbH, Ulm, Germany 
Physiological saline solution DeltaSelect GmbH, Dreieich, Germany 
Aqua B.Braun Ecotainer® B.Braun Melsungen AG, Melsungen, Germany 
Sodium bicarbonate 8.4% Serag-Wiessner KG, Naila, Germany 
Krebs-Henseleit electrolyte solution Serag-Wiessner KG, Naila, Germany 
Apocynin Sigma-Aldrich, Steinheim, Germany 
Baytril 2.5% Bayer, Leverkusen, Germany 
Superoxide dismutase from bovine 
erythrocytes 
Sigma-Aldrich, Steinheim, Germany 
EDTA Fluka Biochemika, Buchs, Switzerland 
RPMI1640 PAN Biotech GmbH, Aidenbach, Germany 
Penicillin/Streptomycin PAN Biotech GmbH, Aidenbach, Germany 
Fetal calf serum PAA Labortechnik, Pasching, Austria 
Triton X-100 Merck, Darmstadt, Germany 
Sucrose Sigma-Aldrich, Steinheim, Germany 
Magnesium chloride Sigma-Aldrich, Steinheim, Germany 
Tris-HCl Sigma-Aldrich, Steinheim, Germany 
Tween 20 Sigma-Aldrich, Steinheim, Germany 
Nonidet P-40 Qiagen, Hilden, Germany 
Proteinase K Qiagen, Hilden, Germany 
RED Taq DNA polymerase Sigma-Aldrich, Hamburg, Germany 
100bp DNA Ladder Promega, Mannheim, Germany 
Agarose (electrophoresis grade) Fluka Biochemika, Buchs, Switzerland 
Deoxy nucleotide mix (dNTPs) Promega, Mannheim, Germany 
Ethidium bromide Sigma-Aldrich, Steinheim, Germany 
Sodium chloride Fluka Biochemika, Buchs, Switzerland 
Potassium dihydrogen phosphate Merk, Darmstadt, Germany 
Potassium chloride Fluka Biochemika, Buchs, Switzerland 
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Chelex 100 Resin BioRad Laboratories, Hercules, CA, USA 
Magnesium chloride hexahydrate Fluka Biochemika, Buchs, Switzerland 
Calcium chloride dihydrate Fluka Biochemika, Buchs, Switzerland 
D-(+)-glucose anhydrous Fluka Biochemika, Buchs, Switzerland 
Oncotic agent HAES® Fresenius Kabi, Bad Homburg, Germany 
DTPA Sigma-Aldrich, Munich, Germany 
NaOH Merck, Darmstadt, Germany 
CPH.Hydrochloride Alexis Biochemicals, San Diego, CA, USA 
Ketavet (Ketamin hydrochlorid) Pfizer Pharma GmbH, Karlsruhe, Germany 
Rompun 2% (Xylazin hyrdochlorid) Bayer, Leverkusen, Germany 
Acrylamide  Roth GmbH & Co. KG, München, Germany 
TEMED Roth GmbH & Co. KG, München, Germany 
APS Sigma-Aldrich, Saint Louis, Misouri, USA 
β-mercaptoethanol Sigma-Aldrich, Saint Louis, Misouri, USA 
Methanol J.T. Baker, Holland 
Skim milk powder Fluka Biochemika, Buchs, Switzerland 
Sodium dodecyl sulfate Roth GmbH & Co. KG, Munich, Germany 
ECL Advance Western Blotting 
Detection Kit 
Amersham, GE Healthcare UK Ltd, 
Buckinghamshire, UK 
Bio-Rad Dc protein assay kit Bio-Rad Laboratories, Hercules, USA 
Anti-β-actin Sigma-Aldrich, Saint Louis, Misouri, USA 
iNOS, eNOS and nNOS R&D Systems, Inc, Minneapolis, USA 
Anti-mouse HRP Promega, Mannheim, Germany 
Anti-goat Santa Cruz Biotechnology, Inc, Heidelberg, 
Germany 
Endothelial Cell Growth Medium 
(+Funganose) 
Promocell (Heidelberg, Germany) 
HBSS Mg++/Ca++ Promocell (Heidelberg, Germany) 
 
3.2. Consumables 
Single use syringes Inject Luer®, 1 ml, 
10 ml, 20 ml 
Braun, Melsungen, Germany 
BD Microlance needles 21G, 26G Becton Dickinson, Heidelberg, Germany 
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Sterile gauze 5 x 4 cm Fuhrmann Verbandstoffe GmbH, Munich, 
Germany 
Single use gloves Transaflex® Ansell, Surbiton Surrey, UK 
Gauze balls size 6 Fuhrman Verrbandstoffe GmbH, Munich, 
Germany 
Napkins Tork, Mannheim, Germany 
Threads Nr. 12 Coats GmbH, Kenzingen, Germany 
Surgical threads non-absorbable 
ETHIBOND EXCEL®, size 5-0 
Ethicon GmbH, Norderstedt, Germany 
Surgical instruments Martin Medizintechnik, Tuttlingen, Germany 
Disposable feather scalpel Feather Safety Razor Co, Ltd, Osaka, Japan 
Pipette tips, blue, yellow, white EPPENDORF, Hamburg, Germany 
Tygon® lab tubing 3603 Cole-Parmer Instruments Company, Vernon 
Hills, Illinois, USA 
Tracheal cannula Hand-made 
Cannula for pulmonary artery 
catheterisation 
Hand-made 
Cannula for left heart catheterisation Hand-made 
Combi-Stopper Intermedica GmbH Kliein-Winternheim, 
Germany 
Combitrans Monitoring-Set B.Braun Melsungen AG, Melsungen, Germany 
Cell Strainer nylon mesh, 40 µm, 100 
µm 
BD Biosciences, Bedford, USA 
Heparinized microcapillary tubes Hämacont, Heilbron, Germany 
Disposable micropipettes intraMARK 
50 µl 
Blaubrand; Brand GmbH, Wertheim, Germany 
Haematocrit sealing compound Blaubrand; Brand GmbH, Wertheim, Germany 
Filter papers Whatman, Schleicher & Schuell GmbH, Dassel, 
Germany 
Steritop Filter GP Express 0.22 µm Millipore, Eschborn, Germany 
PVDF Pall corporation, East Hills, NY, USA 
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3.3. Composition of Krebs-Henseleit solution 
Sodium chloride 120 mM 
Potassium chloride 4.3 mM 
Potassium dihydrogen phosphate 1.1 mM 
Calcium chloride 2.4 mM 
Magnesium chloride 1.3 mM 
Glucose 13.32 mM 
Hydroxyethylamylopectin (molecular 
weight 200,000) 
5% (wt/vol) 
 
Krebs-Henseleit solution was used as perfusion buffer. 24 mM of sodium bicarbonate was 
added to perfusion buffer in order to adjust pH at 7.35-7.45. 
 
3.4. Systems and machines for animal experiments 
Peristaltic pump REGLO Digital MS-
4/12
Ismatech SA, Labortechnik-Analytik, 
Glattbrugg, Switzerland 
Piston pump Minivent Type 845 Hugo Sachs Elektronik Harvard Apparatus, 
GmbH, March-Hugstetten, Germany 
Transbridge BM4 World Precision Instruments, Berlin, Germany 
Thermomix UB Braun Melsungen, Melsungen, Germany 
Frigomix1495 Braun Melsungen, Melsungen, Germany 
Research Grade Isometric Force 
Transducer 
Harvard Apparatus, Holliston, USA 
Cole Parmer Masterflex Peristaltic 
Pump Easy-load 7518-10 
Cole Parmer, Vernon Hills, IL, USA 
Harvard respirator cat/rabbit ventilator 
6025 
Hugo Sachs Elektronik, March Hugstetten, 
Germany 
Force Transducer Type U1A Hottinger Baldwin Messtechnik, Fuchstal, 
Germany 
Analog-to-digital transformer PCLD-
8115 wiring terminal board Rev. A2 
Advantech, Feldkirchen, Germany 
Air heater Enda ET 1311 Enda, Horb a.N, Germany 
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Blood analyser ABL 330 Radiometer, Copenhagen, Denmark 
PCR-thermocycler Biometra, Goettingen, Germany 
DNA/RNA Electrophoreis unit Biometra, Goettingen, Germany 
Chemie Genius Bio Imaging System Syngene, Cambridge, UK 
Neubauer hemocytometer L-Optik, Berlin, Germany 
Microlitre centrifuge cooled Mikro 
200R 
Andreas Hettich GmbH & Co KG, Tuttlingen, 
Germany 
Centrifuge Rotina 46R Andreas Hettich GmbH & Co KG, Tuttlingen, 
Germany 
Magnetic stirrer Ret-Basic IKA Labortechnik, Stauffen, Germany 
MiniScope MS100 Magnettech, Berlin-Adlershof, Germany 
SDS-PAGE electrophoresis system Bio-Rad Laboratories GmbH, Munich, 
Germany 
Semi-dry western blot system Bio-Rad Laboratories GmbH, Munich, 
Germany 
Shaker Keutz Labortechnik, Reisskirchen, Germany 
 
 
3.5. Software 
MiniScopeControl, version 2.4.1, ©Dmitri Vashkevich 
Data Acquisition Software LABTECH NOTEBOOK, version 10.1 
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4. Methods 
4.1. Animals 
All animal experiments were in accordance with institutional guidelines. 
Male New Zealand Wight rabbits (body weight 2.8-3.5 kg) were used. 
Male wild-type (WT) C57BL/6J mice (26−30 g) were purchased from Charles River 
Laboratories (Sulzfeld, Germany). Male Nox2 knockout (KO) mice (C57Bl/6.129S6-
Cybbtm1Din/J) were obtained from Jackson Laboratories (Bar Harbor, ME, USA). 
 
 
 
Figure 4. Isolated perfused and ventilated mouse lung. 
 
 
4.2. Isolated ventilated and perfused lungs 
Isolated perfused and ventilated lungs have long been used by investigators interested in the 
physiological, biochemical, and metabolic aspects of this complex organ.46 This technique 
has also been adapted to study pathomechanisms underlying IR injury. We employed warm 
ischemia in isolated perfused lungs as this model permits uncomplicated measurement of 
relevant physiological variables including vascular pressures, membrane permeability, and 
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fluid balance. In addition, cells in the isolated perfused lung are maintained in their "normal" 
anatomical and physiological associations and local physiological regulations are maintained 
in the organ. We took advantage of isolated mouse lungs as this model allows use of 
different genetically altered animals in order to identify the role of specific genes. 
 
4.2.1. Isolation, perfusion and ventilation of rabbit lungs 
The technique of isolated rabbit lung perfusion was performed as described46 with 
modifications. Rabbits were deeply anesthetized with intravenous ketamine (30-50 mg/kg) 
and xylazine (6-10 mg/kg) and anticoagulated with intravenous heparin (1,000 U/kg body 
weight). A median incision was made in the center of the neck, and the trachea was exposed 
by blunt dissection and partially transected. Animals were then intubated via a tracheostoma 
and were room air ventilated (tidal volume, 30 ml; respiratory rate, 30 breaths/min; positive 
end−expiratory, 1 cm H2O) with a Harvard respirator (cat/rabbit ventilator 6025, Hugo 
Sachs Elektronik, March Hugstetten, Germany). 
 
After midsternal thoracotomy, the ribs were spread, and the right ventricle was incised, and 
a fluid-filled perfusion catheter was immediately placed into the pulmonary artery and 
secured with a ligature. Immediately after insertion of the catheter, perfusion (Cole Parmer 
Masterflex Peristaltic Pump Masterflex Easy-load 7518-10, Cole Parmer, Vernon Hills, IL, 
USA) with sterile ice-cold Krebs-Henseleit solution (Serag-Wiessner, Naila, Germany) was 
started, and the heart was cut open at the apex. In parallel with the onset of artificial 
perfusion, ventilation was changed from room air to a pre-mixed normoxic normocapnic gas 
mixture of 21% O2, 5.3% CO2, balanced with N2 (Air Liquide, Deutschland GmbH, 
Ludwigshafen, Germany). 
 
Next, the trachea, lungs, and heart were excised en bloc from the thoracic cage (without 
interruption of ventilation and perfusion) and were freely suspended from a force transducer 
to monitor lung weight gain. A second perfusion catheter with a bent cannula at its tip was 
introduced via the left ventricle into the left atrium and was fixed by suture in this position. 
Meanwhile, the flow was slowly increased from 20 to 100 mL/min (total system volume 250 
mL). After rinsing the lungs with >1 L buffer to wash out blood, the perfusion circuit was 
closed for recirculation. Left atrial pressure was set at 2.0 mm Hg to ensure zone III 
conditions throughout the lung at end-expiration. The isolated, perfused lung was placed in a 
temperature-equilibrated housing chamber, and the whole system (perfusate reservoirs, 
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tubing, housing chambers) was heated to 37.5°C. Additionally, the inspiration loop of the 
ventilation system was connected to a humidifier and heated to 37.5°C. 
Pressures in the pulmonary artery (Ppa), the left atrium and the trachea were registered by 
means of pressure transducers connected to the perfusion catheters via small diameter tubing 
and were digitised with an analog-to-digital converter, thus allowing data sampling with a 
personal computer. The transducers were calibrated at zero to the hilum level before 
every measurement. 
 
4.2.2. Isolation, perfusion and ventilation of mouse lungs 
The technique of isolated mouse lung perfusion was performed as described106 with 
modifications. Mice were deeply anesthetised intraperitoneally with pentobarbital sodium 
(100 mg/kg body weight) and anticoagulated with intravenous heparin (500 U/kg body 
weight). A median incision was made in the center of the neck, and the trachea was exposed 
by blunt dissection and partially transected. Animals were then intubated via a tracheostoma 
and were room air ventilated (tidal volume, 300 µL; respiratory rate, 90 breaths/min; 
positive end−expiratory pressure, 3 cm H2O) with a specific piston pump (Minivent Type 
845; Hugo Sachs Elektronik, March-Hugstetten, Germany). 
 
After midsternal thoracotomy, the ribs were spread, the heart was incised at the apex, the 
right ventricle was incised, and a fluid-filled perfusion catheter was immediately placed into 
the pulmonary artery and secured with a ligature. Immediately after insertion of the catheter, 
perfusion (REGLO Digital MS-4/12; Ismatec SA, Labortechnik-Analytik, Glattbrugg, 
Switzerland) with sterile ice-cold Krebs-Henseleit solution (Serag-Wiessner, Naila, 
Germany) was started. In parallel with the onset of artificial perfusion, ventilation was 
changed from room air to a pre-mixed normoxic normocapnic gas mixture of 21% O2, 5.3% 
CO2, balanced with N2 (Air Liquide, Deutschland GmbH, Ludwigshafen, Germany). 
 
Next, the trachea, lungs and heart were excised en bloc from the thoracic cage (without 
interrupting ventilation and perfusion) and were freely suspended from a force transducer to 
monitor lung weight gain. A second perfusion catheter with a bent cannula at its tip was 
introduced via the left ventricle into the left atrium. Meanwhile, the flow was slowly 
increased from 0.2 to 2 mL/min (total system volume: 15 mL). After rinsing the lungs with 
>20 mL buffer to wash out blood, the perfusion circuit was closed for recirculation. Left 
atrial pressure was set at 2.0 mm Hg. The isolated, perfused lung was placed in a 
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temperature-equilibrated housing chamber, and the whole system (perfusate reservoirs, 
tubing, housing chambers) was heated to 37.5°C. 
 
 
 
 
Figure 5. Schematic representation of the experimental set-up of the isolated perfused 
mouse lung. AMP - amplifier, BT – bubble trap, FT – force transducer, GN – normoxic gas 
supply, GN – anoxic gas supply, IC – intraluminal catheter, LV – left ventricle, PA – 
pulmonary artery, PC – perfusion catheter, PEEP – positive end-expiratory pressure, PT – 
pressure transducer, R – reservoir, RP – roller pump, REC – recording device, T – trachea, 
V – ventilator. From Seeger et al. Methods Enzymol. 1994;233:549-84 with modifications. 
 
Pressures in the pulmonary artery (Ppa), the left atrium and the trachea were registered by 
means of pressure transducers connected to the perfusion catheters via small diameter tubing 
and were digitised with an analog-to-digital converter, thus allowing data sampling with a 
personal computer (Fig. 5). The transducers were calibrated at zero to the hilum level 
before every measurement. 
 
4.2.3. Vascular compliance measurements 
The vascular compliance (change in vascular volume per change in microvascular pressure) 
was calculated from the initial, rapid phase of weight gain, occurring within 1-2 min after 
onset of venous pressure elevation. Increase in the vascular compliance may signal increase 
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in the capillary surface area, which is a determinant of the microvascular pressure step-
induced fluid filtration, since both the site of main capillary filtration and the capacity of the 
pulmonary circulation are located in the microcirculation. Significant rises of Kfc values in 
the absence of any augmentation of vascular compliance thus indicate that increased 
hydraulic conductivity of the microvascular walls and not increased capillary surface area 
was the predominant underlying event.46 
 
4.2.4. Vascular permeability measurements 
For assessment of lung vascular permeability we utilized the approach of the measurement 
of transvascular fluid filtration under conditions of hydrostatic challenge (capillary filtration 
coefficient), as described.46 During this sudden venous pressure elevation by 7.5-mmHg for 
8 min flow was maintained and ventilation was not interrupted. This maneuver induced an 
initial rapid weight gain (within 1 min), representing predominantly enhanced vascular 
filling, and a subsequent slow phase of weight gain, reflecting transvascular fluid filtration. 
 
In control lungs and even most injured lungs, the rate of weight gain between 2 and 8 min 
after pressure elevation steadily decreases, due to rising interstitial pressure, 
counterbalancing the increase in microvascular filtration pressure. Therefore, time zero 
extrapolation of the slope of the weight gain curve was performed, using a semilogarithmic 
plot of the weight gain according to Taylor and Gaar (1969). The Kfc was then calculated by 
use of the extrapolated initial rate of fluid filtration, expressed in cubic centimetres per 
second per gram wet lung weight per millimeter Hg microvascular pressure increase (in 
terms of the elevation in venous pressure) x10-4. 
 
4.2.5. Assessment of pulmonary edema 
In addition to the calculation of Kfc values, the hydrostatic challenge-induced net lung 
weight gain was assessed. Lungs were freely suspended from a force transducer for weight 
monitoring. Lung weight gain was calculated as the weight difference before and 5 min after 
each hydrostatic challenge maneuver. It reflects changes in the microvascular hydraulic 
conductivity. 
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4.3. Western Blot Assay 
The lungs were removed and immediately frozen in liquid nitrogen. They were then 
homogenised in lysis buffer containing 50 mM tris-(hydroxymethyl)-aminomethane 
(Tris)/HCl (pH 7.6), 150 mM NaCl, 10 mM CaCl2, 60 mM NaN3, 0.1% wt/vol Triton X-100 
and a cocktail of protease inhibitors (Complete™ Protease Inhibitor Cocktail Tablets; 
Boehringer, Ingelheim, Germany) using a tissue homogenizer. Homogenates were 
centrifuged at 13,000 rpm at 4°C for 30 minutes. The supernatants were measured for 
protein content using Dye Reagent Concentrate (Bio-Rad Laboratories, München, 
Germany). Extracts containing equal amounts of protein (60 μg) were denatured by boiling 
for 10 minutes in Laemmli’s buffer containing β-mercaptoethanol and separated on 8% 
SDS-polyacrylamide gels at 100 V. The separated proteins were transferred to PVDF 
membranes with a semidry transfer unit at 115mA for 1 hour 15 minutes. The blots were 
blocked with 6 % non fat milk powder solution and developed with specific goat polyclonal 
IgG antibodies: eNOS and nNOS (R&D Systems, Inc, Minneapolis, USA), 1:1000 and 
mouse polyclonal IgG antibody: iNOS (R&D Systems, Inc, Minneapolis, USA), 1:1000 and 
donkey anti-goat HRP-labeled secondary antibody (Santa Cruz: 1:5000) for eNOS and 
nNOS and goat anti-mouse HRP for iNOS. The bands were visualized using an enhanced 
chemiluminescence ECL Plus Western blotting detection reagents (Amersham Biosciences, 
Freiburg, Germany) and quantified by densitometry (Syngene, VWR). Density values are 
expressed relative to the β-actin (Sigma-Aldrich) control level of each sample. All densities 
reported are means and SEM of four separate experiments. 
 
 
4.4. Measurement of nitrite and nitrate in perfusate 
Nitrite/nitrate levels were measured in the perfusate samples using Griess reagent according 
to manufacturer’s instructions (Sigma, Germany). Perfusate probes were sampled from 
venous effluent, aliquoted, and frozen immediately, and stored at -20°C until measurement. 
For measurement, 100 µl of perfusate was mixed with 100 µl of Griess reagent, 10 min and 
then 100 µl vanadium chloride was added. After 35 min incubation at 37ºC, the light 
absorbance at 540 nm was measured. Concentrations of nitrite/nitrate were calculated by 
plotting of achieved values against a calibration curve. Calibration curves were generated by 
serial dilutions of sodium nitrite of known concentrations in the same buffer as used for 
experiments. 
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4.5. Ischemia-reperfusion in living mice 
The WT and Nox2 KO mice were anaesthetized by an intraperitoneal injection of ketamine 
(100 mg/kg) and xylazine (8 mg/kg). During the experiment the depth of anesthesia was 
adjusted in accordance to the toe-pinch reflex. An additional dose of ketamine (30 mg/kg) 
was given when necessary. Mice were placed into a custom-made heating chamber (37°C) 
to maintain body temperature during the entire experiment. Endotracheal intubation with a 
21-gauge atraumatic cannula was performed through a tracheotomy, and mechanical 
ventilation was initiated (130 breaths/min, 225 μL stroke volume, and a positive-end 
expiratory pressure of 2 cm H2O) with an inspiratory oxygen fraction of 50% using a mouse 
ventilator MiniVent type 845 (Hugo Sachs Elektronik, March-Hugstetten, Germany). To 
compensate for possible fluid losses saline was administered at a rate of 0.2 ml/hour. The 
left thoracic wall was shaved and disinfected. After a left anterolateral thoracotomy through 
the third left intercostal space, all animals were given 500 IU/kg heparin 
intrapercutaneously. Five minutes after heparin administration the pulmonary hilum of the 
left lung, including the bronchus, pulmonary artery, and pulmonary vein, was occluded for 
90 minutes using a noncrushing microsurgical clamp to create lung ischemia under the left 
lung in an inflated state. With removal of the clamp, the left lung was reperfused and 
reventilated for 90 minutes. In time-matched sham-operated animals served as controls, a 
thoracotomy was performed without occlusion of the hilum. At the end of the reperfusion 
period, animals were sacrificed, and the left lungs were excised for assessment of tissue 
water content. 
 
 
4.6. Wet-to-dry lung weight ratio 
As a measure of pulmonary edema formation, wet-to-dry lung weight ratios were 
determined for left lungs. For this purpose, total lung weight was measured before (wet 
weight) and after a 48-hour drying process at an oven (Fisher Isotemp, 65°C) (dry weight). 
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4.7. Generation of chimeric mice 
To evaluate the relative contributions of NADPH oxidase expressed by resident leukocytes 
and phagocyte-type NADPH oxidase expressed by endothelial cells, we assessed the effect 
of selective reconstitution or inactivation of leukocyte NADPH oxidase on IR-induced lung 
injury. 
 
 
Irradiation
Bone marrow cells
 
 
Figure 6. Schematic representation of chimeric mice generation. 
 
 
4.7.1. Technique of bone marrow (BM) transplantation 
Chimeric mice were produced as described107 with modifications (Fig. 6). Donor mice (8 to 
10 weeks old) were anticoagulated with an intraperitoneal injection of heparin (500 U) and 
then anesthetised by spontaneous inhalation of isoflurane and euthanized by cervical 
dislocation. After dissection of the femora and tibiae under the fume hood, the muscles were 
peeled off with sterile cotton swabs and the bones were put into cold medium on ice. Under 
the sterile cell culture hood bone ends were cut off with a scalpel. The bone shafts were then 
flushed with 21G needle on 5 mLl syringe with RPMI 1640 containing 1% FCS, 100 U/mL 
penicillin and 1000 U/mL streptomycin directly into 15 mL Falcon tube. The harvested bone 
marrow was centrifuged 5 min at 400xg at 4 °C. The supernatant was discarded and the 
pellet was resuspended in 1 mL medium by repeated pipetting and transferred into new 
Falcon tube through 100 µm nylon mesh. The cell strainer was rinsed with 1 mL medium. 
Afterwards the suspension was centrifuged 5 min at 400xg at 4 °C, the supernatant was 
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discarded and the cells were cooled on ice for 3 min. Subsequently, erythrocytes were lysed 
by adding 1 mL of ice-cold pure sterile water and gentle pipetting up and down 3-5 times. 
After 30 sec, 10 mL of cold medium were added. Next, the bone marrow was mechanically 
dissociated and filtered through a 40 µm nylon mesh to gain a single cell suspension. The 
cell suspension was then centrifuged 5 min at 400xg at 4 °C. The supernatant was discarded 
and the pellet was resuspended in 1 mL medium by repeated pipetting to produce a single 
cell suspension. Finally, the cells were counted using a Neubauer hemocytometer. About 5 x 
107 mononuclear cells were harvested from each donor. 
 
Recipient mice (8 to 10 weeks old) were BM depleted by lethal irradiation with an 1100-rad 
(11 Gray) 60Co irradiator at a dose rate of ~0.6 Gray/min. Within 6−8 hr of irradiation, 2−5 × 
106 donor BM cells in a volume of 150 µL sterile medium were injected into the lateral tail 
vein of the warmed recipient. BM reconstitution was allowed to occur for >3 months. 
During this time, chimeric mice were housed individually in sterile filter-isolator cages. 
Chimeras were administered Baytryl (10 mg/L; Bayer, Leverkusen, Germany) in sterile 
drinking water for 2 weeks, after which normal drinking water was used. 
 
4.7.2. Types of chimeric mice 
Three different groups of chimeras were generated (Fig. 7). To control for BM 
transplantation procedures, WT-to-WT chimeras (i.e., WT animals that received BM cells 
from WT mice) were generated, thus preserving NADPH oxidase function in all cells. In 
KO-to-WT chimeras, BM cells from Nox2 KO mice were transplanted into WT mice, 
resulting in selective inactivation of NADPH oxidase in BM-derived cells. In WT-to-KO 
chimeras, BM cells harvested from WT animals were transferred to Nox2 KO mice, 
resulting in selective reconstitution of NADPH oxidase in BM-derived cells. 
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WT-to-KOKO-to-WTWT-to-WTNox2 KOWT mouse
BMT Nox2 chimeric mice
 
 
Figure 7. Schematic representation of Nox2 genotype in chimeric mice. Functional 
unaltered Nox2 allele is illustrated with dark coloured cells and disrupted Nox2 allele with 
white coloured cells. From left to right: WT mice, Nox2 KO mice, chimeric WT-to-WT 
mice (WT mice that received bone marrow cells from WT mice), KO-to-WT mice (WT 
mice that received bone marrow cells from Nox2 KO mice), WT-to-KO mice (Nox2 KO 
mice that received bone marrow cells from WT mice). 
 
 
4.8. Genotyping of chimeric mice 
The success of BM transplantation procedures was verified by PCR using genomic DNA 
obtained from blood cells or endothelial cells. 
 
4.8.1. Isolation of genomic DNA from peripheral blood leukocytes 
Genomic DNA of bone marrow derived cells was isolated from peripheral blood of chimeric 
mice. Blood (65−100 µL) was obtained from the lateral tail vein of mice with a heparinized 
microcapillary tube and expelled immediately into a 1.5 mL microfuge tube containing 20 
µL of 10 mmol/L EDTA and mixed immediately to prevent clot formation. Blood was 
stored on ice until processing. Then 800 µL of lysis buffer A (0.32 mol/L Sucrose, 10 
mmol/L Tris-HCl, pH = 7.5), 5 mmol/L MgCl2, 1% v/v Triton X-100) was added to each 
tube and vortexed to suspend evenly. After microfuging at 1300xg for 15 min at 4 °C the 
supernatant was removed and nuclear pellet was resuspended in 1 mL of lysis buffer A. This 
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procedure was repeated two more times, or until no hemoglobin remained. After this steps 
nuclear pellet was resuspended in 100 µL of lysis buffer B (50 mmol/L KCl, 1.5 mmol/L 
MgCl2, 10 mmol/L Tris-HCl, pH = 8.3), 0.45% NP-40, 0.45% Tween 20) with 100 µg/mL 
proteinase K and incubated at 55 °C for 120 min. After that the solution was heated to 97 °C 
for 10 min to inactivate proteinase K. This solution of genomic DNA was further used for 
PCR reaction. 
 
4.8.2. Isolation of genomic DNA from endothelial cells 
Genomic DNA of endothelial cells was isolated from aortic endothelial cells obtained from 
chimeric mice. Endothelial cells were collected after thorough washing of aortas with saline 
by scratching with a scalpel and were then put into 0.2 µL PCR tube with 50 µL of lysis 
buffer B and 100 µg/mL proteinase K. After incubation at 55 °C for 120 min the solution 
was heated to 97 °C for 10 min to inactivate proteinase K. This solution of genomic DNA 
was further used for PCR reaction. 
 
4.8.3. Polymerase chain reaction 
Genomic DNA obtained from peripheral blood cells or endothelial cells was amplified by 
PCR with two Nox2-specific primers and a neomycin-resistant primer (Metabion, 
Martinsried, Germany). The nucleotide sequences of the primers are listed in table 2. Primer 
pair oIMR0517 and oIMR0518 amplifies a 240-bp fragment from the wild-type allele. 
Primer pair oIMR0519 and oIMR0518 amplifies a 195-bp fragment from the disrupted 
allele. 
 
Table 2. Nucleotide sequences of primers used for PCR. 
oIMR0517 5'- AAg AgA AAC TCC TCT gCT gTg AA -3' 23-mer A=8, C=5, G=5, T=5 
oIMR0518 5'- CgC ACT ggA ACC CCT gAg AAA gg -3' 23-mer A=7, C=7, G=7, T=2 
oIMR0519 5'- gTT CTA ATT CCA TCA gAA gCT TAT Cg -3' 26-mer A=7, C=6, G=4, T=9 
 
PCR was performed in a 25-μL reaction mixture containing 200 μmol/L dNTP, 1.5 mmol/L 
MgCl2, 1 μmol/L DNA polymerase buffer, 2 U Taq polymerase (Invitrogen) and 0.4 μmol/L 
of each primer. Composition of the reaction mix for amplifying one sample is shown in table 
3. 
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Table 3. Composition of 25 µL PCR mix for one sample 
Reaction components End volume, µL 
10x PCR buffer 2.5 
25 mmol/L MgCl2 1.5 
1 mmol/L dNTP  5.0 
20 μmol/L primer oIMR0517 1 
20 μmol/L primer oIMR0518 1 
20 μmol/L primer oIMR0519 1 
Template DNA 5 
Red-Taq polymerase, 5 U/μL 1 
Deionised water 7 
 
 
All PCR reagents were mixed together in a 0.2 µL PCR tube, which was then placed in a 
thermal cycler (Biometra, Germany). The cycling conditions are shown in table 4. 
 
Table 4. Cycling conditions for PCR 
Step  Temperature Time Note 
1 Denaturing 94°C 3 min  
2 Denaturing 94°C 20 sec  
3 Annealing 64°C 30 sec -0.5°C per cycle 
4 Elongation 72°C 35 sec go to 2, 12 times 
5 Denaturing 94°C 20 sec  
6 Annealing 64°C 30 sec  
7 Elongation 72°C 35 sec go to 5, 25 times 
8 Elongation 72°C 2 min hold at 10°C 
 
 
4.8.4. DNA agarose gel electrophoresis 
Agarose gel electrophoresis was used for assessing amplified PCR products. Agarose 
powder was mixed with 1xTBE buffer (45 mmol/L Tris (pH 8.0), 45 mmol/L Boric acid and 
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2 mmol/L EDTA) and boiled in a microwave until agarose melted completely. Two µL of 
ethidium bromide were added into the solution and the gel was poured into a horizontal 
apparatus and polymerised for 20 min. 
 
The PCR products were loaded onto the polymerised 2% agarose gel and placed in 
electrophoresis unit. The apparatus was then filled with 1xTBE buffer until it covered 
completely the gel. The gel was run at 110 Volt in gel electrophoresis. After electrophoresis, 
bands on the gel were visualized by Chemie Genius Bio Imaging System (Syngene, 
Cambridge, UK). The fragment size of amplified products was determined by comparing 
with the DNA molecular standard markers which were loaded along with the PCR products: 
240 bp bands corresponded to fragments from wild type allele and 195 bp bands 
corresponded to fragments from disrupted allele. 
 
 
4.9. Measurement of intravascular reactive oxygen species release 
Measurement of ROS in intact organs is largely unresolved. Recently, we established a 
method combining ESR spectroscopy with the spin trapping technique for measurement of 
superoxide release from isolated perfused and ventilated lungs.108 
 
4.9.1. Perfusion buffer preparation 
For ESR measurements isolated mouse lungs were perfused with a modified Krebs-
Henseleit solution, which was prepared with great care from the highest-grade chemicals to 
minimize contamination with transition metals. First, 120 mmo/L sodium chloride, 1.1 
mmol/L potassium dihydrogen phosphate and 4.3 mmol/L potassium chloride were added to 
ultrapure water (Milli-Q, Millipore GmbH, Schwalbach, Germany). Then the solution was 
treated with 50 g/L chelator Chelex 100 Resin under constant stirring at room temperature 
for 4 hr. Afterwards the solution was first strained through filter paper (Whatman, 
Schleicher & Schuell GmbH, Dassel, Germany) using a funnel and then filter-sterilized 
(0.22 µm, Steritop, Millipore). After sterile filtration 2.4 mmol/L calcium chloride, 5 
mmol/L glucose and 50 g/L hydroxyethyl starch (HAES) were added and stirred and then 
filter-sterilized. This solution was then kept at 4 °C until use in the experiments. 
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4.9.2. Spin probe preparation 
Intravascular ROS release was measured by ESR spectroscopy using the spin probe 1-
hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine (CPH; Alexis Corporation, San Diego, 
CA, USA), as described108, 109 with modifications. Stock solutions of CPH (10 mmol/L) 
dissolved in 0.9% NaCl that contained 1 mmol/L diethylenetriamine-pentaacetic acid 
(DTPA) and was purged with argon were prepared daily and kept under argon on ice. DTPA 
was used to decrease CPH autooxidation, which is catalyzed by trace amounts of transition 
metals. 
 
4.9.3. ESR spectroscopy settings 
The ESR settings were as follows: microwave frequency 9.78 GHz, modulation frequency 
100 kHz, modulation amplitude 2 G, microwave power 18 mW. More detailed information 
on ESR spectroscopy settings is provided in table 5. 
Table 5. Parameters of ESR spectroscopy 
Parameters Values 
B0-Field 3379.4G 
Sweep width 58.52G 
Sweep time 15 sec 
Number 3 
Smooth 0 sec (inactive) 
Steps 4096 
Modulation amplitude 2000mG 
Power attenuation 10 dB 
Receiver gain 500 
Signal phase 180 (inversed) 
 
 
4.9.4. ROS measurements 
ESR samples were placed into 50 μl capillary tubes and measured at room temperature. 
Oxidation of the spin probe CPH by ROS leads to formation of the stable nitroxide radical 
3-carboxy-proxyl (CP•). The amount of nitroxide formed is proportional to the concentration 
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of the reacted oxidant species. ROS formation was measured from the kinetics of nitroxide 
accumulation by following the ESR amplitude of the low-field component of ESR spectra. 
The rate of superoxide radical formation was determined by measuring the SOD-inhibited 
nitroxide generation in separate experiments performed in the presence of SOD in the buffer 
fluid (150 U/ml). 
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Figure 8. Typical ESR spectrum of CP• nitroxide. The triple-line spectrum of CP• radical 
resulting from the reaction of the spin probe CPH with ROS was detected using a MS 100 
spectrometer (Magnettech, Berlin, Germany). 
 
 
4.10. Endothelial cell culture 
4.10.1. Isolation of human umbilical vein endothelial cells (HUVEC) from umbilical 
cord 
The cord was laid on Petri dish and excess blood was dabbed off with gauze. Fresh cuts on 
both ends of the cord were made with a scalpel. At one end, a feeding needle was inserted 
carefully into the vein without damaging the surrounding tissue and fixed in place with a 
clamp. The umbilical vein was rinsed with 100 ml of HBSS Mg++/Ca++ (Promocell). After 
clamping the other end of the vein, the cord was filled with collagenase until there was 
moderate distention of the vein. The cord was then incubated for 20 min. Afterwards, the 
cord was placed on a soft surface and gently massaged 2-3 times to facilitate cell 
detachment. The vein was washed with 30 ml of HBS and the cells were collected in a 
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prepared sterile 50 ml Falcon tube with 1 ml FCS. The Falcone tube was spinned at 1200 
rpm for 5 min at room temperature. The supernatant was carefully aspirated, and the pellet 
of cells was resuspended in Endothelial Cell Growth Medium (+Funganose) (Promocell) and 
plated in a gelatinized 75 mm flask. 
 
4.10.2. Anoxia-reoxygenation protocol in endothelial cell culture 
After HUVECs reached 80% confluent, they were spitted on the gelatinized 30mm 
coverslips. The cells were incubated at 37°C with 5% CO2 for 2 days. Coverslips were then 
placed in a 0.162 ml volume glass-covered perfusion chamber (Pecon, Germany), perfused 
(1 ml/min) with Hepes-Ringer buffer (HRB; 136.4 mmol/L NaCl, 5.6 mmol/L KCl/1 
mmol/L MgCl2, 2.2 mmol/L CaCl2, 10 mml/L Hepes, 5 mmol/L glucose, pH 7.4) saturated 
with 21% O2 (normoxia, pO2 ≈ 150 mmHg), and maintained at 37 ± 0.2°C by heating both 
the HRB and the chamber. Anoxia was induced by switching the perfusing HRB from 
normoxic to anoxic (continuously purged with 100% N2). After a 90 min period of anoxia, 
reoxygenation was initiated by exposing the endothelial cells to normoxic HRB for 20 min. 
Time-matched control normoxic endothelial cells were exposed to normoxic HRB. Separate 
experiments from each study were performed with HUVECs from different human sources. 
 
4.10.3. ROS measurement in endothelial cell anoxia-reoxygenation 
Endothelial ROS release was measured by ESR spectroscopy using the spin probe CPH 
(Alexis Corporation, San Diego, CA, USA), as described with modifications.109 Stock 
solutions of CPH (10 mmol/L) dissolved in 0.9% NaCl that contained 1 mmol/L 
diethylenetriamine-pentaacetic acid (DTPA) and was purged with argon were prepared daily 
and kept under argon on ice. DTPA was used to decrease CPH autooxidation, which is 
catalyzed by trace amounts of transition metals. The spin probe, CPH (1 mmol/L), was 
added into the HRB at the end of ischemic period 5 min before the onset of reperfusion. 
Samples from the outflow of the chamber with HUVECs were collected in 50-µL glass 
capillary tubes and measured immediately at room temperature. Samples were collected 
every 2 min starting 10 min before reperfusion and during reperfusion for 20 min. 
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4.11. Data analysis 
Values are presented as the mean ± SEM. A Student’s t-test was used to compare two 
groups. For multiple comparisons, a one-way analysis of variance followed by a Student-
Newman-Keuls post hoc test was performed. p < 0.05 was considered statistically 
significant. 
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5. Results 
5.1. Effects of ischemia and reperfusion on rabbit lungs 
To investigate the role of NADPH oxidase in IR-induced lung injury, we assessed the effects 
of selective inhibition of NADPH oxidase on vascular permeability and intravascular ROS 
release in rabbit lungs. 
 
5.1.1. Hemodynamic data 
There were no significant differences in basal Ppa between different experimental groups. 
After 240 min of anoxic ischemia, a moderate and transient increase in Ppa followed by a 
decrease to baseline levels was observed upon reperfusion of rabbit lungs. Apocynin pre-
treatment slightly suppressed the pressure response (Table 6). 
 
Table 6. Pulmonary artery pressure in rabbit lungs. 
 Ppa bas, mm Hg Ppa rep, mm Hg 
IR 6.8 (0.2) 16.8 (1.9) 
Non-ischemic control 7.7 (0.1) 7.6 (0.2) 
IR + apocynin 7.5 (0.3) 15.2 (0.9) 
 
Data are presented as mean (SEM) of 4-6 independent experiments. Ppa bas – baseline 
pulmonary artery pressure before starting ischemia; Ppa rep – pulmonary artery pressure 
increase on reperfusion; IR – untreated lungs subjected to ischemia/reperfusion; non-
ischemic control lungs were continuously perfused and normoxically ventilated; 
IR+apocynin – untreated lungs subjected to ischemia/reperfusion and pretreated with 
apocynin (0.5 mM). 
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5.1.2. Vascular compliance 
Vascular compliance values were not significantly different between nonischemic control 
lungs and the different experimental groups and were virtually constant throughout the 
entire experimental period (Table 7). 
 
Table 7. Vascular compliance in rabbit lungs. 
Vascular compliance, cm3/mm Hg 
Time after onset of reperfusion, min 
 
Pre 
30 60 90 
IR 0.39 (0.04) 0.48 (0.01) 0.54 (0.01) 0.54 (0.01) 
Non-ischemic control 0.51 (0.02) 0.52 (0.02) 0.55 (0.02) 0.57 (0.01) 
IR + apocynin 0.55 (0.02) 0.48 (0.04) 0.62 (0.02) 0.61 (0.01) 
 
 
Data are presented as mean (SEM) of 4-6 independent experiments. pre – baseline values 
before starting ischemia; IR – untreated lungs subjected to ischemia/reperfusion; non-
ischemic control lungs were continuously perfused and normoxically ventilated; 
IR+apocynin – untreated lungs subjected to ischemia/reperfusion and pretreated with 
apocynin (0.5 mM). 
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5.1.3. Vascular permeability 
In nonischemic rabbit lungs Kfc values were virtually constant throughout the entire 
experimental period. Ischemia and reperfusion resulted in increased microvascular 
permeability in untreated rabbit lungs. In parallel, massive edema formation was observed, 
and experiments had to be discontinued 60 min after the onset of reperfusion due to 
excessive fluid accumulation. Inhibition of the NADPH oxidase by apocynin significantly 
attenuated vascular leakage (Figure 9). 
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Figure 9. Vascular permeability in rabbit lungs. Lungs were exposed to anoxic ischemia for 
240 min with following reperfusion. Time-matched non-ischemic control lungs did not 
undergo ischemia but were continuously perfused and normoxically ventilated. Kfc values 
were assessed, as described in Methods. Ischemia and reperfusion resulted in increased 
vascular permeability in lungs from the untreated IR group. Administration of apocynin 
significantly attenuated lung injury. Data are presented as mean + SEM of 4-6 independent 
experiments. *p<0.05 compared with non-ischemic control group, †p<0.05 compared with 
IR+apocynin group. Kfc – capillary filtration coefficient; pre – baseline values before 
starting ischemia; IR – untreated lungs subjected to ischemia/reperfusion; IR+apocynin – 
untreated lungs subjected to ischemia/reperfusion and pretreated with apocynin (0.5 mM). 
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5.1.4. Pulmonary edema formation 
In nonischemic rabbit lungs only marginal lung weight gain was observed throughout the 
entire experimental period. Ischemia and reperfusion induced massive edema formation in 
untreated rabbit lungs, and experiments had to be discontinued 60 min after the onset of 
reperfusion. Inhibition of the NADPH oxidase by apocynin significantly attenuated lung 
fluid accumulation (Figure 10). 
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Figure 10. Lung weight gain in rabbit lungs. Lungs were exposed to anoxic ischemia for 
240 min with following reperfusion. Time-matched non-ischemic control lungs did not 
undergo ischemia but were continuously perfused and normoxically ventilated. Lung weight 
gain was assessed, as described in Methods. Ischemia and reperfusion resulted in increased 
lung fluid accumulation in lungs from the untreated IR group. Administration of apocynin 
significantly attenuated vascular leakage. Data are presented as mean + SEM of 4-6 
independent experiments. *p<0.05 compared with non-ischemic control group, †p<0.05 
compared with IR+apocynin group. pre – baseline values before starting ischemia; IR – 
untreated lungs subjected to ischemia/reperfusion; IR+apocynin – untreated lungs subjected 
to ischemia/reperfusion and pretreated with apocynin (0.5 mM) 
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5.1.5. Intravascular ROS release 
Reperfusion of previously ischemic untreated rabbit lungs was associated with increased 
intravascular ROS release, when compared to nonischemic lungs. Parallel experiments in the 
presence of SOD revealed that the major portion of it was due to superoxide release. 
Inhibition of the NADPH oxidase by apocynin significantly reduced intravascular ROS 
release (Figure 11). 
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Figure 11. Intravascular ROS release in rabbit lungs. Lungs were exposed to anoxic 
ischemia for 240 min with following reperfusion. Time-matched non-ischemic control lungs 
did not undergo ischemia but were continuously perfused and normoxically ventilated. Spin 
probe CPH was added into perfusate 5 min before reperfusion. Samples from the venous 
outflow of the isolated lung were taken and measured immediately by ESR spectroscopy. 
The contribution of superoxide radical was determined in the presence of SOD in the buffer 
fluid. Increased ROS generation upon reperfusion of untreated IR lungs was reduced by 
SOD. Administration of apocynin decreased ROS generation as well. Data are presented as 
mean + SEM of 4-6 independent experiments. *p<0.05 compared with all other groups. non-
isch contr – non-ischemic control; IR – untreated lungs subjected to ischemia/reperfusion; 
IR+SOD – untreated lungs subjected to ischemia/reperfusion and pretreated with superoxide 
dismutase (150 U/ml); IR+apocynin – untreated lungs subjected to ischemia/reperfusion and 
pretreated with apocynin (0.5 mM). 
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5.2. Effects of ischemia and reperfusion on lungs from WT and Nox2 KO mice 
To investigate the role of phagocyte-type NADPH oxidase in IR-induced lung injury, we 
assessed the effects of selective inhibition of NADPH oxidase and genetic deficiency of its 
catalytic subunit Nox2 on IR-induced injury in lungs from WT and Nox2 KO mice. 
 
5.2.1. Hemodynamic data 
There were no significant differences in basal Ppa between different experimental groups. In 
non-ischemic control lungs, pulmonary artery pressure values were essentially constant 
throughout the entire experimental period. After 90 min of anoxic ischemia, a moderate, 
transient increase in pulmonary artery pressure was followed by a decrease to baseline levels 
upon reperfusion of WT mouse lungs. Apocynin pre-treatment non-significantly suppressed 
the pressure response. In lungs from Nox2 KO mice the pressure response on reperfusion 
was attenuated to a similar extent (Table 8). 
 
Table 8. Pulmonary artery pressure in WT and Nox2 KO mouse lungs. 
 Ppa bas, mm Hg Ppa rep, mm Hg 
WT 8.1 (0.1) 11.6 (0.2) 
Non-ischemic control 8.1 (0.2)  
WT + SOD 8.2 (0.2) 11.4 (0.4) 
WT + apocynin 8.0 (0.3) 9.8 (0.3) 
Nox2 KO 7.7 (0.1) 9.9 (0.2) 
 
Data are presented as mean (SEM) of 4-6 independent experiments. Ppa bas – baseline 
pulmonary artery pressure before starting ischemia; Ppa rep – pulmonary artery pressure 
increase on reperfusion; WT – lungs from wild type mice subjected to ischemia/reperfusion; 
non-ischemic control lungs were continuously perfused and normoxically ventilated; 
WT+SOD – lungs from wild type mice subjected to ischemia/reperfusion and pretreated 
with superoxide dismutase (150 U/ml); WT+apocynin – lungs from wild type mice 
subjected to ischemia/reperfusion and pretreated with apocynin (0.5 mM); Nox2 KO – lungs 
from Nox2 knock-out mice subjected to ischemia/reperfusion. 
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5.2.2. Vascular compliance 
Vascular compliance values were not significantly different between nonischemic control 
lungs and the different experimental groups and were virtually constant throughout the 
entire experimental period (Table 9). 
 
Table 9. Vascular compliance in WT and Nox2 KO mouse lungs. 
Vascular compliance, cm3/mm Hg 
Time after onset of reperfusion, min 
 
Pre 
30 60 90 
WT 0.01 (0.002) 0.01 (0.002) 0.01 (0.002) 0.01 (0.002) 
Non-ischemic control 0.01 (0.001) 0.01 (0.001) 0.01 (0.001) 0.01 (0.001) 
WT + SOD 0.01 (0.002) 0.01 (0.002) 0.01 (0.002) 0.01 (0.002) 
WT + apocynin 0.01 (0.001) 0.01 (0.001) 0.01 (0.001) 0.01 (0.001) 
Nox2 KO 0.01 (0.001) 0.01 (0.001) 0.01 (0.001) 0.01 (0.001) 
 
 
Data are presented as mean (SEM) of 4-6 independent experiments. pre – baseline values 
before starting ischemia; WT – lungs from wild type mice subjected to 
ischemia/reperfusion; non-ischemic control lungs were continuously perfused and 
normoxically ventilated; WT+SOD – lungs from wild type mice subjected to 
ischemia/reperfusion and pretreated with superoxide dismutase (150 U/ml); WT+apocynin – 
lungs from wild type mice subjected to ischemia/reperfusion and pretreated with apocynin 
(0.5 mM); Nox2 KO – lungs from Nox2 knock-out mice subjected to ischemia/reperfusion. 
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5.2.3. Vascular permeability 
There were no significant differences in baseline Kfc values among the different 
experimental groups (Figure 12). In non-ischemic lungs, Kfc values were essentially 
constant throughout the entire experimental period (Figure 12). Ischemia and reperfusion 
resulted in increased microvascular permeability in lungs from WT mice compared with 
time-matched non-ischemic control lungs (Figure 12). Inhibition of NADPH oxidase by 
apocynin as well as superoxide anion scavenging by SOD significantly attenuated vascular 
leakage (Figure 12). Similarly, lungs from mice with an NADPH oxidase deficiency (i.e., 
Nox2 KO mice) were protected against tissue injury (Figure 12). 
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Figure 12. Vascular permeability in lungs from WT and Nox2 KO mice. Lungs were 
exposed to anoxic ischemia for 90 min with following reperfusion. Time-matched non-
ischemic control lungs from WT mice did not undergo ischemia but were continuously 
perfused and normoxically ventilated. Kfc values were assessed, as described in Methods. 
Ischemia and reperfusion resulted in increased vascular permeability in lungs from WT 
mice. Pretreatment with apocynin as well as SOD significantly attenuated lung injury. Nox2 
KO mouse lungs were protected against injury. Data are presented as mean + SEM of 4-6 
independent experiments. *p<0.05 compared with all other groups. Kfc – capillary filtration 
coefficient; pre – baseline values before starting ischemia; WT – lungs from wild type mice 
subjected to ischemia/reperfusion; WT+SOD – lungs from wild type mice subjected to 
ischemia/reperfusion and pretreated with superoxide dismutase (150 U/ml); WT+apocynin – 
lungs from wild type mice subjected to ischemia/reperfusion and pretreated with apocynin 
(0.5 mM); Nox2 KO – lungs from Nox2 knock-out mice subjected to ischemia/reperfusion. 
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5.2.4. Pulmonary edema formation 
In non-ischemic lungs, only marginal lung weight gain was observed throughout the entire 
experimental period (Figure 13). Ischemia and reperfusion resulted in increased fluid 
accumulation in lungs from WT mice compared with time-matched non-ischemic control 
lungs (Figure 13). Inhibition of NADPH oxidase by apocynin as well as superoxide anion 
scavenging by SOD significantly reduced edema (Figure 13). Similarly, lungs from mice 
with an NADPH oxidase deficiency (i.e., Nox2 KO mice) were protected against tissue 
injury (Figure 13). 
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Figure 13. Lung weight gain in lungs from WT and Nox2 KO mice. Lungs were exposed to 
anoxic ischemia for 90 min with following reperfusion. Time-matched non-ischemic control 
lungs from WT mice did not undergo ischemia but were continuously perfused and 
normoxically ventilated. Lung weight gain was assessed, as described in Methods. Ischemia 
and reperfusion resulted in increased lung fluid accumulation in lungs from WT mice. 
Pretreatment with apocynin as well as SOD significantly attenuated vascular leakage. Nox2 
KO mouse lungs were protected against injury. Data are presented as mean + SEM of 4-6 
independent experiments. *p<0.05 compared with all other groups. pre – baseline data 
before starting ischemia; WT – lungs from wild type mice subjected to 
ischemia/reperfusion; WT+SOD – lungs from wild type mice subjected to 
ischemia/reperfusion and pretreated with superoxide dismutase (150 U/ml); WT+apocynin – 
lungs from wild type mice subjected to ischemia/reperfusion and pretreated with apocynin 
(0.5 mM); Nox2 KO – lungs from Nox2 knock-out mice subjected to ischemia/reperfusion. 
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5.2.5. Intravascular ROS release 
Reperfusion of previously ischemic lungs from WT mice was associated with increased 
intravascular ROS release as compared with time-matched non-ischemic control lungs 
(Figure 14). Parallel experiments in the presence of SOD revealed that the majority of ROS 
release was caused by superoxide (Figure 14). Inhibition of NADPH oxidase by apocynin 
significantly decreased ROS production (Figure 14). Moreover, in mice lacking Nox2, the 
catalytic NADPH oxidase subunit, intravascular ROS release was significantly attenuated 
(Figure 14). 
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Figure 14. Intravascular ROS release in lungs from WT and Nox2 KO mice. Lungs were 
exposed to anoxic ischemia for 90 min with following reperfusion. Time-matched non-
ischemic control lungs did not undergo ischemia but were continuously perfused. Spin probe 
CPH was added into perfusate 5 min before reperfusion. Samples from the venous outflow 
of the isolated lung were taken and measured immediately by ESR spectroscopy. The 
contribution of superoxide radical was determined in parallel experiments performed in the 
presence of SOD (150 U/ml) in the buffer fluid. Increased ROS generation upon reperfusion 
of WT mouse lungs was reduced by SOD and was attenuated in lungs from Nox2 KO mice. 
Data are presented as mean + SEM of 4-6 independent experiments. *p<0.05 compared with 
all other groups. WT – lungs from wild type mice subjected to ischemia/reperfusion; non-
isch contr – non-ischemic control; WT+apocynin – lungs from wild type mice subjected to 
ischemia/reperfusion and pretreated with apocynin (0.5 mM); Nox2 KO – lungs from Nox2 
knock-out mice subjected to ischemia/reperfusion. 
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5.2.6. Expression of different NOS isoforms in lungs from WT and Nox2 KO mice 
Baseline expression of eNOS and nNOS in lungs from Nox2 KO mice was not significantly 
different from that in lungs from WT mice (Figure 15). No baseline expression of iNOS was 
detected in lungs from WT and Nox2 KO mice (Figure 15). 
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Figure 15. NOS expression in Nox2-deficiency. (A) Expression of NOS isoenzymes in 
lungs from WT and Nox2 KO mice. Proteins were extracted from the lungs and subjected to 
Western blot. (B) The bar graph illustrates the quantification of eNOS/nNOS expression 
levels normalized to β-actin levels. All data are presented as means + SEM of 4 animals in 
each group. 
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5.2.7. NO production in lungs from WT and Nox2 KO mice 
 
The levels of NO metabolites in Nox2 KO mice were not significantly different from those 
in WT animals (Figure 16). 
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Figure 16. NO production in lungs from WT and Nox2 KO mice. All isolated lungs were 
continuously perfused and normoxically ventilated and perfusate samples were taken after 
perfusion for 30 min. Accumulation of NO metabolites was determined in perfusate samples 
by the Griess reaction. There were no significant differences in intravascular NO metabolites 
accumulation among the groups. Data are presented as mean + SEM of 5-7 independent 
experiments. 
 
 
 
 52
                                                                                                                                         Results 
5.3. Effects of lung ischemia and reperfusion in living WT and Nox2 KO 
mice 
To further elucidate the pathobiological role of NADPH oxidase on IR-induced lung injury 
in an in vivo situation we investigated lung edema formation in anesthetized mice during 
ischemia-reperfusion. While WT mice developed severe edema, Nox2-deficient mice were 
completely protected (Figure 17). 
 
WT Nox2 KO
W
et
-to
-D
ry
 W
ei
gh
t R
at
io
 G
ai
n
0
1
2
3
4
5
*
 
Figure 17. Pulmonary edema formation in living mice. Lung edema was analyzed by 
quantitative assessment of wet-to-dry weight ratios of ischemia-exposed lungs from wild-
type (WT; n = 5) and Nox2-deficient (Nox2 KO; n = 5) mice which were normalized to 
sham-operated mice (n = 5 in each group). For ischemia left lungs were exposed to 1.5 hours 
of ischemia, followed by 1.5 hours of reperfusion. Values are given as mean ± SEM. * P < 
0.05. 
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5.4. Characterization of chimeric mice 
The efficiency of reconstituting BM-derived cells in chimeric mice was assessed by PCR 10 
weeks after irradiation and transplantation. In all chimeric mice examined PCR band 
patterns of genomic DNA obtained from peripheral blood cells changed from the recipient 
pattern to donor pattern, indicative of successful reconstitution of bone marrow-derived cells 
by transplantation (Figure 18). Unaltered Nox2 allele was present in endothelial cells, as 
well as in leukocytes, of control WT-to-WT chimeric mice (Figure 18). In KO-to-WT 
chimeric mice, unaltered Nox2 allele was present in endothelial cells, whereas leukocytes 
contained a disrupted Nox2 allele (Figure 18). Conversely, in WT-to-KO chimeras, a 
disrupted Nox2 allele was present in endothelial cells, but leukocytes contained an unaltered 
Nox2 allele (Figure 18). 
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Figure 18. Genotypes in chimeric mice. WT, Nox2 KO and chimeric mice were genotyped 
by PCR using genomic DNA obtained from blood cells or endothelial cells with the Nox2-
specific primers and the neomycin-resistant primer. WT = 240 bp, KO = 195 bp. In WT-to-
WT mice in all cells unaltered Nox2 allele was present, similar to WT mice. In KO-to-WT 
mice unaltered allele was present in recipient endothelial cells, whereas in all donor bone 
marrow-derived cells disrupted allele was present. In WT-to-KO mice unaltered allele was 
limited to donor bone marrow-derived cells with disrupted allele present in recipient 
endothelial cells. Leuk. – leukocytes, End. – endothelial cells, WT – wild-type, KO – knock-
out. 
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5.5. Effects of ischemia and reperfusion on lungs from chimeric mice 
To evaluate the relative contributions of NADPH oxidase expressed by resident leukocytes 
and phagocyte-type NADPH oxidase expressed by endothelial cells, we assessed the effect 
of selective reconstitution or inactivation of leukocyte NADPH oxidase on IR-induced lung 
injury. 
 
5.5.1. Hemodynamic data 
A moderate and transient increase in pulmonary artery pressure was followed by a return to 
baseline levels upon reperfusion of lungs from chimeric mice (Table 10). Basal pulmonary 
artery pressure values and pressure responses after reperfusion did not differ significantly 
between the different experimental groups (Table 10). 
 
Table 10. Pulmonary artery pressure in chimeric mouse lungs. 
 Ppa basal, mm Hg Ppa reperfusion, mm Hg 
WT 8.1 (0.1) 11.6 (0.2) 
WT-to-WT 8.1 (0.1) 11.4 (0.3) 
KO-to-WT 8.4 (0.2) 11.3 (0.1) 
WT-to-KO 8.2 (0.2) 10.8 (0.2) 
 
Data are presented as mean (SEM) of 4-6 independent experiments. Ppa basal – baseline 
pulmonary artery pressure, Ppa rep – pulmonary artery pressure increase on reperfusion; WT 
– lungs from wild type mice subjected to ischemia/reperfusion; WT-to-WT – lungs from 
control chimeric mice; KO-to-WT – lung from chimeric mice with selective inactivation of 
NADPH oxidase in leukocytes subjected to ischemia/reperfusion; WT-to-KO – lungs from 
chimeric mice with selective reconstitution of NADPH oxidase in leukocytes subjected to 
ischemia/reperfusion. 
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5.5.2. Vascular compliance 
Vascular compliances were not significantly different between WT mouse lungs and the 
different groups of chimeric mouse lungs and were virtually constant throughout the entire 
experimental period (Table 11). 
Table 11. Vascular compliance in chimeric mouse lungs. 
Vascular compliance, cm3/mm Hg 
Time after onset of reperfusion, min 
 
Pre 
30 60 90 
WT 0.01 (0.002) 0.01 (0.002) 0.01 (0.002) 0.01 (0.002) 
WT-to-WT 0.01 (0.001) 0.01 (0.001) 0.01 (0.001) 0.01 (0.001) 
KO-to-WT 0.01 (0.001) 0.01 (0.001) 0.01 (0.002) 0.01 (0.002) 
WT-to-KO 0.01 (0.002) 0.01 (0.002) 0.01 (0.002) 0.01 (0.002) 
 
 
Data are presented as mean (SEM) of 4-6 independent experiments. pre – baseline values 
before starting ischemia; WT – lungs from wild type mice subjected to 
ischemia/reperfusion; WT-to-WT – lungs from control chimeric mice; KO-to-WT – lung 
from chimeric mice with selective inactivation of NADPH oxidase in leukocytes subjected 
to ischemia/reperfusion; WT-to-KO – lungs from chimeric mice with selective 
reconstitution of NADPH oxidase in leukocytes subjected to ischemia/reperfusion. 
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5.5.3. Vascular permeability 
Baseline Kfc values were similar among the different experimental groups (Figure 19). The 
severity of IR-induced increase in microvascular permeability in lungs from WT-to-WT and 
KO-to-WT chimeric mice was comparable to that in WT mouse lungs (Figures 12 and 19). 
In contrast, the dramatic rise in Kfc was significantly attenuated in lungs from WT-to-KO 
chimeric mice (Figure 19). 
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Figure 19. Vascular permeability in lungs from chimeric mice. Lungs were exposed to 
anoxic ischemia for 90 min with following reperfusion. Kfc values were assessed, as 
described in Methods. Ischemia and reperfusion resulted in increased vascular permeability 
in lungs from control WT-to-WT and KO-to-WT chimeric mice. In lungs from WT-to-KO 
chimeric mice the dramatic rise in Kfc was significantly attenuated. Data are presented as 
mean + SEM of 4-6 independent experiments. *p<0.05 compared with all other groups. Kfc 
– capillary filtration coefficient, pre – baseline values before starting ischemia; WT – lungs 
from wild type mice subjected to ischemia/reperfusion; WT-to-WT – lungs from control 
chimeric mice subjected to ischemia/reperfusion; KO-to-WT – lung from chimeric mice 
with selective inactivation of NADPH oxidase in leukocytes subjected to 
ischemia/reperfusion; WT-to-KO – lungs from chimeric mice with selective reconstitution 
of NADPH oxidase in leukocytes subjected to ischemia/reperfusion. 
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5.5.4. Pulmonary edema formation 
The severity of IR-induced edema in lungs from WT-to-WT and KO-to-WT chimeric mice 
was comparable to that in WT mouse lungs (Figures 13 and 20). In contrast, the severe fluid 
accumulation was significantly attenuated in lungs from WT-to-KO chimeric mice (Figure 
20). 
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Figure 20. Lung weight gain in lungs from chimeric mice. Lungs were exposed to anoxic 
ischemia for 90 min with following reperfusion. Lung weight gain was assessed, as 
described in Methods. Ischemia and reperfusion resulted in severe lung edema formation in 
lungs from control WT-to-WT and KO-to-WT chimeric mice. In lungs from WT-to-KO 
chimeric mice fluid accumulation was significantly attenuated. Data are presented as mean + 
SEM of 4-6 independent experiments. *p<0.05 compared with all other groups. pre – 
baseline values before starting ischemia; WT – lungs from wild type mice subjected to 
ischemia/reperfusion; WT-to-WT – lungs from control chimeric mice subjected to 
ischemia/reperfusion; KO-to-WT – lung from chimeric mice with selective inactivation of 
NADPH oxidase in leukocytes subjected to ischemia/reperfusion; WT-to-KO – lungs from 
chimeric mice with selective reconstitution of NADPH oxidase in leukocytes subjected to 
ischemia/reperfusion. 
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5.5.5. Intravascular ROS release 
The reperfusion-induced increase in intravascular ROS release in previously ischemic lungs 
from WT-to-WT mice was comparable in magnitude to that in WT lungs (Figures 14 and 
21). Parallel experiments in the presence of SOD revealed that the major portion of it was 
due to superoxide release (Figure 21). Attenuated intravascular ROS release was observed in 
the two other groups of chimeric mice (KO-to-WT and WT-to-KO; Figure 21). 
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Figure 21. Intravascular ROS release in lungs from chimeric mice. Lungs were exposed to 
anoxic ischemia for 90 min with following reperfusion. Spin probe CPH was added into 
perfusate 5 min before reperfusion. Samples from the venous outflow of the isolated lung 
were taken and measured immediately by ESR spectroscopy. The contribution of superoxide 
radical was determined in parallel experiments performed in the presence of superoxide 
dismutase (SOD) in the buffer fluid (150 U/ml). Increased ROS generation upon reperfusion 
of lungs from WT-to-WT chimeric mice was reduced by SOD and was attenuated in lungs 
from KO-to-WT and WT-to-KO mice. Data are presented as mean + SEM of 4-6 
independent experiments. *p<0.05 compared with KO-to-WT and WT-to-KO mice. WT – 
lungs from wild type mice subjected to ischemia/reperfusion; WT-to-WT – lungs from 
control chimeric mice subjected to ischemia/reperfusion; KO-to-WT – lung from chimeric 
mice with selective inactivation of NADPH oxidase in leukocytes subjected to 
ischemia/reperfusion; WT-to-KO – lungs from chimeric mice with selective reconstitution 
of NADPH oxidase in leukocytes subjected to ischemia/reperfusion. 
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5.6. Effects of anoxia-reoxygenation on endothelial ROS production 
Exposure of HUVEC monolayers to 90 min anoxia followed by 20 min reoxygenation 
resulted in significant increase in ROS production (Figure 22). 
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Figure 22. Effects of anoxia-reoxygenation on endothelial ROS production. Superoxide 
anion production by HUVECs submitted to normoxia or anoxia-reoxygenation measured by 
ESR spectroscopy. Data are presented as mean + SEM of 4-6 independent experiments. 
*p<0.05 compared with normoxic control. 
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6. Discussion 
In the present study we demonstrated that oxidative stress plays a role in lung IR injury by 
directly measuring enhanced intravascular ROS release from isolated perfused lungs from 
rabbits and WT mice. We also showed that ROS were derived from NADPH oxidase as 
pretreatment with apocynin, an NADPH oxidase inhibitor, significantly attenuated vascular 
injury after reperfusion of lungs from rabbits and WT mice. Moreover, tissue injury was 
significantly attenuated in lungs from mice lacking NADPH oxidase catalytic subunit Nox2. 
Furthermore, Nox2-deficient mice were completely protected from IR-induced lung injury 
in an in vivo situation. Finally, we demonstrated that endothelial, but not leukocyte, NADPH 
oxidase mediates lung injury during the early reperfusion phase. 
 
6.1. Role of NADPH oxidase in ischemia/reperfusion-induced lung injury 
We employed a model of warm ischemia in isolated lungs to induce a massive leakage 
response as reflected by severe pulmonary edema formation on reperfusion in lungs from 
rabbits and WT mice. A transient increase in Ppa was observed upon reperfusion of the 
lungs. The extent of this pressor response was rather limited as perfusion was re-established 
with gradual increase in flow. This pressure response could not account for the edema 
formation observed in the reperfused lungs, since Ppa increase was transient and returned to 
baseline levels in the majority of experiments. Moreover, the microvascular pressure levels 
measured in parallel with the permeability assessment in the same model were only 
marginally affected and did not significantly differ between the preischemic and 
postischemic hydrostatic challenge maneuvers.110 Thus, the edema formation in the post-
ischemic lungs in this model was independent of hydrostatic forces, and must be attributed 
to impaired pulmonary microvascular permeability, which was evident from the significant 
increase in the Kfc values. Although in lungs from Nox2 KO mice and in lungs from rabbits 
and WT mice treated with apocynin the pressure response was attenuated, this suppression 
was only moderate. In addition, the increase in Ppa followed by a decrease to baseline levels 
so that there were no significant differences between different groups in the Ppa values 
assessed at the time points of hydrostatic challenge for measurement of Kfc. Therefore, the 
protective effects of pharmacological inhibition of NADPH oxidase and NADPH oxidase 
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deficiency against IR lung injury must be primarily ascribed to maintenance of capillary 
endothelial barrier function. 
 
In lungs from rabbits and WT mice, ischemia and reperfusion resulted in increased vascular 
permeability and edema formation associated with increased intravascular ROS release. 
Increased ROS generation during reperfusion after ischemia contributes to tissue injury, 
microvascular dysfunction, increased endothelial permeability and endothelial “stunning”.44 
With respect to the lung, IR causes microvascular damage, an increase in capillary 
permeability, and acute pulmonary edema.111 Previous efforts to clarify the source of ROS 
have, however, produced inconsistent results. Our observation that exogenously 
administered SOD attenuated IR-induced lung injury suggests that superoxide anions are 
critical for this process. This hypothesis is further supported by the observation that SOD 
also attenuated the ROS signal. 
 
Although there are many enzymes that can potentially produce superoxide anions in the 
lung, including uncoupled NO synthase, xanthine oxidase, cytochrome P450 and 
mitochondrial respiratory chain enzymes,71 the contribution of these enzymes to the vascular 
generation of ROS is relatively minor compared with NADPH oxidase. Numerous studies 
have shown that NADPH oxidase−derived ROS can promote and modulate oxygen radical 
production by other sources, thereby amplifying the total amounts of ROS.58 Selective 
inhibition of NADPH oxidase with apocynin attenuated the IR-induced increase in 
pulmonary vascular permeability in lungs from rabbits and WT mice, demonstrating the role 
of NADPH oxidase in our model of ischemia and reperfusion. The selectivity of apocynin 
for NADPH oxidase has been well characterized.97 Apocynin impedes the assembly of the 
p47phox and p67phox subunits within the membrane NADPH oxidase complex, thereby 
blocking formation of an active enzyme and preventing ROS generation.97 In animal 
models, apocynin affords protection against IR-induced lung injury.112, 113 Favorable effects 
of inhibiting NADPH oxidase were further confirmed by experiments with mice lacking 
Nox2, the main catalytic subunit of the enzyme, and in in vivo experiments. Reperfusion of 
isolated lungs from Nox2 KO mice was also associated with suppressed ROS production 
during the first minutes of reperfusion. 
 
As superoxide reacts with nitric oxide (NO) and limits its bioavailability, reduced 
production of superoxide in Nox2 KO mice has been suggested to result in an increase in 
NO bioavailability114. In support of this idea, there is an increased 24-hour urinary excretion 
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of NO metabolites in conscious Nox2 KO mice.115 Aortic segments from Nox2 KO mice 
exhibit a more pronounced endothelium-dependent relaxation to acetylcholine than that 
observed in aortae from WT animals.114 The ROS scavenger tiron increases endothelium-
dependent relaxation in WT mice, indicating that the reduced scavenging of endothelial NO 
by superoxide in the aorta from Nox2 KO mice could account for the enhanced relaxation.114 
Therefore, it is possible that increased bioavailability of NO could contribute to attenuation 
of lung injury in Nox2 KO mice. Alternatively, increased NO levels in Nox2 KO mice 
reported by some authors115 might derive from compensatory changes in expression of 
enzymes producing NO. 
 
Gene knockout approaches have helped to better understand the functions of different 
proteins. However, some results obtained from these knockout mice are unexpected and 
differ from the results of pharmacological intervention experiments. One possible 
explanation for this is that germ-line gene deletion with subsequent loss of function of a 
particular protein can induce changes in expression and/or function of other proteins with 
related function that can compensate for the loss of its function. For example, compensatory 
changes have been reported within the cAMP-dependent protein kinase system in mice 
deficient for specific cAMP-dependent protein kinase subunits.116 The phagocyte NADPH 
oxidase is a critical component of innate immunity, responsible for generation of 
microbicidal ROS. The second genetically established antimicrobial mechanism of 
macrophages is production of reactive nitrogen species by inducible NO synthase (iNOS). 
There is evidence that NADPH oxidase and iNOS compensate for each other's deficiency in 
providing resistance to indigenous bacteria.117 In addition, beneficial effects of NO and 
cGMP in lung IR have been reported118, 119. Macrophages from Nox2 KO mice produce 
more NO metabolites than WT animals,120 supporting the idea of the potential compensatory 
changes in NADPH oxidase deficient mice. 
 
To address these issues we compared expression and function of NO synthases in Nox2 KO 
mice with those in WT animals. We could not demonstrate any changes in baseline 
expression of constitutive NO synthases in lungs from Nox2 KO mice from that in lungs 
from WT mice. No baseline expression of iNOS was detected in lungs from WT and Nox2 
KO mice Furthermore, the levels of NO metabolites in perfusate sample from Nox2 KO 
lungs were not significantly different from those in WT animals. Thus, we could not provide 
any evidence for compensatory changes in expression of NO synthases or increased 
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bioavailability of NO in Nox2 KO mice that might contribute to protection against IR lung 
injury. 
 
The classical phagocyte-type NADPH oxidase was first described in neutrophils. Initially, 
this enzyme was thought to be a non-specific host defense mechanism against a variety of 
pathogens that was expressed specifically in phagocytes. NADPH oxidase has subsequently 
been shown, however, to have important physiological roles in phagocytes and also to 
contribute to the pathophysiology of many inflammatory diseases.72 Circulating 
polymorphonuclear leukocytes play a pivotal role in IR lung injury121-125; yet the 
involvement of intrapulmonary resident leukocytes in oxidant lung injury remains 
controversial. It has recently been shown that the pulmonary capillary bed is the site of large 
marginated pools of leukocytes that contain 0.6−3 times the total number of circulating 
ones.126, 127 Marginated neutrophils roll along the vessel wall, making transient contact with 
the endothelial cells without being firmly adherent.128 Approximately 65% of the marginated 
neutrophils are in parenchymal vessels, primarily alveolar capillaries.128 These large 
leukocyte populations display very slow washout kinetics even after extensive 
extracorporeal buffer perfusion,129 assuming their role in reperfusion injury in isolated lung 
experiments. 
 
Several different nonphagocytic cell types, including endothelial cells, vascular smooth cells 
and adventitial fibroblasts, constitutively express a superoxide-generating enzyme analogous 
to the NADPH oxidase of neutrophils.55, 75, 130, 131 Moreover, a phagocyte-type of NADPH 
oxidase in endothelial cells is a major source of ROS production in endothelial cells114 and is 
a predominant contributor to overall vascular ROS production.77 Thus, endothelial cells or 
resident pulmonary leukocytes, or both cell types, may be the cellular source of the NADPH 
oxidase−derived superoxide anion during IR. 
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6.2 Role of endothelial NADPH oxidase in IR-induced lung injury 
Although the late phase is dependent on neutrophil recruitment and activation, the early 
injury is neutrophil-independent and occurs by 15 minutes of reperfusion. As early injury 
occurs well before significant tissue neutrophil infiltration has occurred, it is likely 
dependent on lung resident cells. 
 
To assess the contribution of NADPH oxidase from different resident cell types to IR-
induced lung injury we used chimeric mice. Lungs from control chimeric animals (WT mice 
that received BM-derived cells from WT animals) exhibited IR-induced vascular injury 
comparable with that observed in lungs from WT mice, indicating that the irradiation and 
BM transfer procedures, per se, did not interfere with IR response. Selective reconstitution 
of NADPH oxidase on BM-derived cells in Nox2 KO mice did not abolish the protection 
afforded by a global deficiency of NADPH oxidase, in accordance with other reports that 
leukocytes are not essential for the initiation of IR injury.29 Using an isolated rat lung 
perfusion model, Deeb et al.28 demonstrated that ROS are involved in IR injury but 
neutrophils are not, because adding neutrophils did not enhance the injury. In addition, 
Dodd-o et al.113 explored a genetic predisposition to lung IR in different mouse strains. 
Although they found that apocynin, an NAPDH oxidase inhibitor, attenuated lung injury, 
strain-dependent neutrophil−derived ROS production was not correlated with IR injury, 
suggesting that genetic differences in neutrophil NADPH oxidase activity do not determine 
the severity of IR injury. 
 
Recently, it was demonstrated in an in vivo mouse model using chimeras created by BM 
transplantation between WT and p47phox KO mice that NADPH oxidase in BM−derived 
cells mediates pulmonary IR injury.132 There may be several explanations for the 
discrepancy between our study and that of Yang et al. In contrast to our study, Yang et al. 
investigated the role of NADPH oxidase in IR lung injury using p47phox KO mice. 
Differential responses to different challenges in these two strains of NADPH oxidase KO 
mice have been reported. For example, a discrepancy in inflammatory response was 
observed between p47phox and Nox2 KO mice in response to chronic smoke exposure.133 In 
addition, differential effect of p47phox and Nox2 deficiency on the course of pneumococcal 
meningitis has been demonstrated.134 The reason for these differences is not clear but may 
be related to the activation of other vascular Nox enzymes by p47phox and/or different 
cellular distributions and functions of p47phox and Nox2 besides their role in ROS 
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production. In addition, we used a buffer-perfused model that eliminates contribution from 
circulating neutrophils and investigated the role of NADPH oxidase expressed in resident 
lung cells in early reperfusion. On the contrary, Yang et al.132 demonstrated that NADPH 
oxidase−generated ROS from circulating BM-derived cells contribute to lung IR injury in 
the later phase of reperfusion. A biphasic pattern of IR injury was recently demonstrated, in 
which the first lung injury peak during early reperfusion was neutrophil independent and the 
second peak, in the later phase of reperfusion, was neutrophil mediated.30 Finally, it is well 
known, that the severity of IR injury is determined by both the duration and the extent of 
blood flow decrease to an organ or tissue.15 In the study of Yang et al. left lungs were 
exposed to 1 h ischemic period so that the injury might be much milder than that in our 
experiments. Therefore, the first peak of injury might be significantly diminished. 
 
Our finding that resident leukocytes are not necessary to initiate lung injury, at least in the 
early phase of reperfusion, in isolated perfused mouse lungs does not, however, exclude the 
possibility that leukocytes might be primed by products produced during IR and may 
subsequently contribute to lung injury during later phases of reperfusion. ROS generated 
during endothelial hypoxia and reoxygenation stimulate MAP kinase signaling and kinase-
dependent neutrophil recruitment.135 
 
Thus, under transplant conditions, resident donor lung cells, rather than resident donor or 
circulating recipient leukocytes, may initiate IR injury. In support of this hypothesis, 
macrophages play a more important role in the early phase of reperfusion.35, 39, 136 Depleting 
alveolar macrophages protects against lung IR injury, which supports a role for macrophages 
in the development of lung injury.38 Macrophages can be depleted or inactivated by using 
clodronate liposomes or gadolinium chloride. However, it is well known that gadolinium 
salts can produce a wide variety of changes in physiology, because gadolinium chloride 
inhibits stretch-activated ion channels and physiological responses of tissues to mechanical 
stimulation.137. Liposome-encapsulated clodronate (clodronate-liposome) is transported into 
local macrophages by phagocytosis, and, after digestion, clodronate is released and induces 
cellular death. Clodronate-liposomes administered intratracheally have been used to deplete 
alveolar macrophages in some studies.38-40 
 
Lung IR injury is associated with alterations in pulmonary surfactant composition and 
activity.138 Pulmonary surfactant is a complex of macromolecular aggregates composed of 
phospholipids and surfactant proteins that is essential for maintenance of normal lung 
 66
                                                                                                                                   Discussion 
function. Exogenous surfactant treatment before ischemia139 or just before reperfusion 
improves the immediate lung transplant function in rats.140 Intratracheally administered 
surfactant improves animal survival and decreases lung IR injury.141, 142 Alveolar 
macrophage depletion with clodronate liposomes causes a severalfold increase in surfactant 
pool sizes in rats,143 which underscores the role of alveolar macrophages in the catabolism of 
surfactant lipids and proteins.144 Thus, surfactant accumulation after alveolar macrophages 
depletion may have important implications in the studies investigating the role of alveolar 
macrophages in lung IR injury and it may have contributed to the outcome of those studies. 
 
NADPH oxidase deficient mice are characterized by slowly progressive late spontaneous 
lung emphysema development.145 NADPH oxidase deficiency is also associated with 
increased influx of macrophages into the lungs with enhanced release of chemokines and 
cytokines.133 Although, we used in our experiments NADPH oxidase deficient mice of 
younger ages before the development of lung emphysema, one would expect augmented 
tissue injury in lungs from Nox2 KO mice. On the contrary, these mice displayed marked 
protection against IR-induced lung injury, thus excluding the potential involvement of 
macrophages in the induction of the injury in our model. 
 
Macrophages and neutrophils are both reconstituted after BM transplantation, and they share 
the same genotype in reciprocal chimeras.146 Sixty days after total body irradiation and BM 
transplantation, most resident lung alveolar macrophages are of donor origin,147 thus 
excluding their role as a ROS-generating source during the induction of lung injury in the 
WT-to-KO chimeric mice in our study. 
 
Selectively inactivating leukocyte NADPH oxidase by transplanting BM-derived cells from 
Nox2 KO mice into WT animals did not reduce IR-induced lung injury, indicating that 
endothelial, but not leukocyte, NADPH oxidase−derived superoxide plays an important role 
in the pathogenesis of early IR injury. Several studies indicate that endothelial NADPH 
oxidase may contribute to ROS production during IR. Stimuli relevant to IR that can activate 
endothelial NADPH oxidase include 1) hypoxia-reoxygenation,148 2) membrane 
depolarization,149 3) flow cessation,150 and 4) nutrient deprivation.151 Pulmonary endothelial-
derived ROS production from this enzyme complex could explain the presence of a PMN 
leukocyte-independent component of lung ischemia/reperfusion injury.136 
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Heumüller et al. 100 recently questioned the ability of apocynin to inhibit an NADPH oxidase 
in endothelial cells. To be effective apocynin has to be converted to an active dimer by 
myeloperoxidase. Heumüller et al.100 reported that the inhibitory action of apocynin for 
NADPH oxidase is restricted to myeloperoxidase-expressing cells. According to the authors, 
in non-phagocytic cells the compound does not inhibit NADPH oxidase but, rather, operates 
as an ROS scavenger.100 However, apocynin can form active dimers in endothelial cells 
through peroxidases other than myeloperoxidase 152. Furthermore, endothelial cells can 
internalize myeloperoxidase released into the vessel by leukocytes.153 These data may 
explain the NADPH oxidase inhibitory effects of apocynin in our study. 
 
Interestingly, both selective reconstitution and inactivation of NADPH oxidase in leukocytes 
were associated with attenuated intravascular ROS release. One possible explanation is that 
ROS is derived from several sources, each of which produces ROS at concentrations below 
the ESR detection limit, which is about 10−9 mol/L under optimal conditions.154 
Consequently, if one (or several) source(s) of ROS is inhibited or deleted, an overall 
reduction in the ROS signal is measured. 
 
In conclusion, our findings indicate that endothelial, but not leukocyte, NADPH 
oxidase−derived superoxide plays an important role in the pathogenesis of lung injury 
during the early phase of reperfusion. Therefore, selective inhibition of NADPH oxidase 
from endothelial cells represents a potential preventive or therapeutic strategy for the 
treatment of IR-induced lung injury. 
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7. Summary 
Pulmonary ischemia/reperfusion lung injury is an important phenomenon encountered in 
many clinical situations, including lung transplantation and thrombolysis after pulmonary 
embolism. Pulmonary IR results in endothelial damage and dysfunction leading to the 
development of high permeability pulmonary edema. Reactive oxygen species (ROS) have 
been implicated in the pathogenesis of lung ischemia/reperfusion (IR) injury, although their 
source(s) remains unclear. 
We studied the role of phagocyte-type NADPH oxidase in this process, using a model of 
isolated buffer-perfused mouse lungs. Ischemia was induced by stopping perfusion for 90 
min. Lung injury was quantified by assessment of lung vascular permeability and fluid 
accumulation during reperfusion. Production of ROS was measured during reperfusion in 
perfusate samples from venous outflow by electron spin resonance spectroscopy using the 
spin probe 1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine. The relative contribution of 
NADPH oxidase expressed on resident leukocytes versus NADPH oxidase on endothelial 
cells was further studied in bone-marrow (BM)-transplanted chimeras. 
In wild-type mouse lungs, IR resulted in increased vascular permeability and edema 
formation that was associated with increased intravascular ROS release. Pretreatment with 
superoxide dismutase or apocynin, an NADPH oxidase inhibitor, significantly attenuated 
lung injury and ROS generation. Nox2 is the catalytic subunit of phagocyte-type NADPH 
oxidase. Decreased tissue injury in lungs from Nox2 knockout mice was associated with 
reduced ROS production. 
The relative contribution of NADPH oxidase expressed by resident leukocytes versus 
endothelial cells was further studied in bone marrow-transplanted chimeras. When NADPH 
oxidase in resident leukocytes was selectively inactivated by transplanting bone marrow 
cells from Nox2 knockout mice into wild-type animals, IR-induced tissue injury was 
comparable to that in wild-type mouse lungs. Conversely, transplanting bone marrow cells 
from wild-type mice into Nox2 knockout animals selectively reconstituted NADPH oxidase 
from resident leukocytes and offered protection against IR-induced lung injury. 
Collectively, these findings suggest that endothelial NADPH oxidase contributes to lung 
injury in early reperfusion, but leukocyte NADPH oxidase does not. 
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8. Zusammenfassung 
 
Das pulmonale Ischämie-Reperfusions(IR)-Syndrom ist gekennzeichnet durch eine schwere 
Beeinträchtigung der Ventilations-/Perfusionsverteilung (Matching), in der Folge einer 
endothelialen Dysfunktion mit erhöhter mikrovaskulärer Permeabilität. Diese 
Organschädigung kann klinisch bis hin zur Entwicklung eines kompletten Lungenversagens 
führen. Diese Form des akuten Organversagens hat eine große klinische Relevanz nach 
Lungentransplantationen sowie bei der operativen oder fibrinolytischen Desobliteration von 
Lungengefäßen nach akuten oder chronisch rezidivierenden Embolien. Reaktiven 
Sauerstoffspezies (ROS) wird eine zentrale Bedeutung für die Pathogenese von IR-Schäden 
beigemessen. Auch bei Ischämie und Reperfusion der pulmonalen Zirkulation wurde eine 
Generierung von ROS nachgewiesen. Trotz zunehmender Erkenntnisse über die 
Mechanismen zur Entstehung des I/R-Syndroms wurde die potenzielle Quelle reaktiver 
Sauerstoffspezies noch nicht eindeutig identifiziert. 
Die im Rahmen dieser Arbeit durchgeführten Untersuchungen erfolgten in isoliert 
perfundierten und ventilierten Lungen von Wildtyp und Nox2-defizienten Mäusen. Die 
Mauslungen wurden Ischämiezeiten von 1,5 Stunden ausgesetzt. Post-ischämische 
Perfusionsstörungen wurden mit Hilfe der Quantifizierung der endothelialen Permeabilität 
durch Messung des kapillären Filtrationskoeffizienten und Nettoflüssigkeitseinlagerung 
evaluiert. Die ROS-Produktion wurde im intakten Organ mit Elektronenspinresonanz-
Spektroskopie (ESR) durch Verwendung des Spin-traps 1-hydroxy-3-carboxy-pyrrolidine 
gemessen und in separaten Experimenten durch Zugabe von Superoxiddismutase (SOD) 
quantifiziert. Zudem wurden durch Knochenmarkstransplantation chimäre Mäuse generiert, 
um die Differenzierung des relativen Anteils der granulozytären versus der endothelialen 
Nox2 am IR-Schaden aufzeigen zu können. 
In Lungen von Wildtyp-Mäusen wurde eine signifikante Superoxid-Freisetzung im 
Anschluss an die Reperfusion nachgewiesen, weiterhin kam es zur Ausbildung eines 
Lungenödems als Zeichen eines Lungenschadens. Die Applikation von SOD und NADPH-
Oxidase-Inhibitor Apocynin zu Beginn der Ischämiephase inhibierte die erhöhte 
Permeabilität und Ödembildung bei der Reperfusion. So konnten wir feststellen, dass die 
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Lungen von Nox2-defizienten vor einem Reperfusionsschaden geschützt waren. Weiterhin 
konnte eine geringere Superoxid-Freisetzung in Lungen von Nox2-defizienten Mäusen 
nachgewiesen werden. 
Die selektive Ausschaltung der NADPH-Oxidase intrapulmonaler Leukozyten durch 
Knochenmarkstransplantation von Nox2-defizienten Mäusen in Wildtypmäuse, zeigte keine 
ödemprotektive Wirkung. Im Gegensatz hierzu, ließ sich die mikrovaskuläre 
Schrankenstörung reduzieren, wenn Knochenmark von Wildtypmäusen in Nox2-defiziente 
Mäuse transplantiert wurde. Erstaunlicherweise konnte eine geringe intravaskuläre ROS-
Freisetzung in den Lungen beider chimärer Mäusestämme gezeigt werden. 
In Anbetracht der gezeigten Ergebnisse konnten wir der endothelialen NADPH-Oxidase die 
Hauptrolle in der Vermittlung des IR-Schadens der Lunge zuordnen, wohingegen 
überraschenderweise die leukozytäre NADPH-Oxidase nur eine nach geordneter Rolle zu 
spielen scheint. 
 
 
 
 71
                                                                                                                                   References 
 
References 
 
1. Parks DA, Shah AK, Granger DN. Oxygen radicals: effects on intestinal vascular 
permeability. Am J Physiol. 1984;247:G167-170. 
2. Christie JD, Kotloff RM, Pochettino A, Arcasoy SM, Rosengard BR, Landis JR, 
Kimmel SE. Clinical risk factors for primary graft failure following lung 
transplantation. Chest. 2003;124:1232-1241. 
3. Sleiman C, Mal H, Fournier M, Duchatelle JP, Icard P, Groussard O, Jebrak G, 
Mollo JL, Raffy O, Roue C, et al. Pulmonary reimplantation response in single-lung 
transplantation. Eur Respir J. 1995;8:5-9. 
4. Christie JD, Bavaria JE, Palevsky HI, Litzky L, Blumenthal NP, Kaiser LR, Kotloff 
RM. Primary graft failure following lung transplantation. Chest. 1998;114:51-60. 
5. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung 
injury. Am J Respir Crit Care Med. 2003;167:490-511. 
6. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Jones DR, Robbins MK, Kron 
IL. Ischemia-reperfusion injury after lung transplantation increases risk of late 
bronchiolitis obliterans syndrome. Ann Thorac Surg. 2002;73:1041-1047; discussion 
1047-1048. 
7. Ward BJ, Pearse DB. Reperfusion pulmonary edema after thrombolytic therapy of 
massive pulmonary embolism. Am Rev Respir Dis. 1988;138:1308-1311. 
8. Levinson RM, Shure D, Moser KM. Reperfusion pulmonary edema after pulmonary 
artery thromboendarterectomy. Am Rev Respir Dis. 1986;134:1241-1245. 
9. Miller WT, Jr., Osiason AW, Langlotz CP, Palevsky HI. Reperfusion edema after 
thromboendarterectomy: radiographic patterns of disease. J Thorac Imaging. 
1998;13:178-183. 
10. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol. 
2005;14:170-175. 
 72
                                                                                                                                   References 
11. Murphy GJ, Angelini GD. Side effects of cardiopulmonary bypass: what is the 
reality? J Card Surg. 2004;19:481-488. 
12. Carvalho EM, Gabriel EA, Salerno TA. Pulmonary protection during cardiac 
surgery: systematic literature review. Asian Cardiovasc Thorac Ann. 2008;16:503-
507. 
13. Adrie C, Laurent I, Monchi M, Cariou A, Dhainaou JF, Spaulding C. 
Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit 
Care. 2004;10:208-212. 
14. Saeed SA, Shad KF, Saleem T, Javed F, Khan MU. Some new prospects in the 
understanding of the molecular basis of the pathogenesis of stroke. Exp Brain Res. 
2007;182:1-10. 
15. Parks DA, Grogaard B, Granger DN. Comparison of partial and complete arterial 
occlusion models for studying intestinal ischemia. Surgery. 1982;92:896-901. 
16. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin 
Invest. 1985;76:1713-1719. 
17. Yung G. Lung transplantation and pulmonary hypertension. Semin Cardiothorac 
Vasc Anesth. 2007;11:149-156. 
18. Kennedy TP, Rao NV, Hopkins C, Pennington L, Tolley E, Hoidal JR. Role of 
reactive oxygen species in reperfusion injury of the rabbit lung. J Clin Invest. 
1989;83:1326-1335. 
19. Ljungman AG, Grum CM, Deeb GM, Bolling SF, Morganroth ML. Inhibition of 
cyclooxygenase metabolite production attenuates ischemia-reperfusion lung injury. 
Am Rev Respir Dis. 1991;143:610-617. 
20. Zamora CA, Baron D, Heffner JE. Washed human platelets prevent ischemia-
reperfusion edema in isolated rabbit lungs. J Appl Physiol. 1991;70:1075-1084. 
21. Pillai R, Bando K, Schueler S, Zebly M, Reitz BA, Baumgartner WA. Leukocyte 
depletion results in excellent heart-lung function after 12 hours of storage. Ann 
Thorac Surg. 1990;50:211-214. 
 73
                                                                                                                                   References 
22. Minamiya Y, Tozawa K, Kitamura M, Saito S, Ogawa J. Platelet-activating factor 
mediates intercellular adhesion molecule-1-dependent radical production in the 
nonhypoxic ischemia rat lung. Am J Respir Cell Mol Biol. 1998;19:150-157. 
23. Moore TM, Khimenko P, Adkins WK, Miyasaka M, Taylor AE. Adhesion molecules 
contribute to ischemia and reperfusion-induced injury in the isolated rat lung. J Appl 
Physiol. 1995;78:2245-2252. 
24. Horgan MJ, Wright SD, Malik AB. Antibody against leukocyte integrin (CD18) 
prevents reperfusion-induced lung vascular injury. Am J Physiol. 1990;259:L315-
319. 
25. Horgan MJ, Ge M, Gu J, Rothlein R, Malik AB. Role of ICAM-1 in neutrophil-
mediated lung vascular injury after occlusion and reperfusion. Am J Physiol. 
1991;261:H1578-1584. 
26. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320:365-376. 
27. Moraes TJ, Zurawska JH, Downey GP. Neutrophil granule contents in the 
pathogenesis of lung injury. Curr Opin Hematol. 2006;13:21-27. 
28. Deeb GM, Grum CM, Lynch MJ, Guynn TP, Gallagher KP, Ljungman AG, Bolling 
SF, Morganroth ML. Neutrophils are not necessary for induction of ischemia-
reperfusion lung injury. J Appl Physiol. 1990;68:374-381. 
29. Steimle CN, Guynn TP, Morganroth ML, Bolling SF, Carr K, Deeb GM. Neutrophils 
are not necessary for ischemia-reperfusion lung injury. Ann Thorac Surg. 
1992;53:64-72; discussion 72-63. 
30. Eppinger MJ, Jones ML, Deeb GM, Bolling SF, Ward PA. Pattern of injury and the 
role of neutrophils in reperfusion injury of rat lung. J Surg Res. 1995;58:713-718. 
31. Brain JD. Lung macrophages: how many kinds are there? What do they do? Am Rev 
Respir Dis. 1988;137:507-509. 
32. Lehnert BE, Valdez YE, Holland LM. Pulmonary macrophages: alveolar and 
interstitial populations. Exp Lung Res. 1985;9:177-190. 
 74
                                                                                                                                   References 
33. Laskin DL, Pendino KJ. Macrophages and inflammatory mediators in tissue injury. 
Annu Rev Pharmacol Toxicol. 1995;35:655-677. 
34. Bowden DH. The alveolar macrophage. Environ Health Perspect. 1984;55:327-341. 
35. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Kron IL. Pulmonary 
macrophages are involved in reperfusion injury after lung transplantation. Ann 
Thorac Surg. 2001;71:1134-1138; discussion 1138-1139. 
36. Fiser SM, Tribble CG, Long SM, Kaza AK, Cope JT, Laubach VE, Kern JA, Kron 
IL. Lung transplant reperfusion injury involves pulmonary macrophages and 
circulating leukocytes in a biphasic response. J Thorac Cardiovasc Surg. 
2001;121:1069-1075. 
37. Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga CH, Goss CH, Mulligan MS. 
Early tumor necrosis factor-alpha release from the pulmonary macrophage in lung 
ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2004;127:1502-1508. 
38. Zhao M, Fernandez LG, Doctor A, Sharma AK, Zarbock A, Tribble CG, Kron IL, 
Laubach VE. Alveolar macrophage activation is a key initiation signal for acute lung 
ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol. 2006;291:L1018-
1026. 
39. Naidu BV, Krishnadasan B, Farivar AS, Woolley SM, Thomas R, Van Rooijen N, 
Verrier ED, Mulligan MS. Early activation of the alveolar macrophage is critical to 
the development of lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 
2003;126:200-207. 
40. Nakamura T, Abu-Dahab R, Menger MD, Schafer U, Vollmar B, Wada H, Lehr CM, 
Schafers HJ. Depletion of alveolar macrophages by clodronate-liposomes aggravates 
ischemia-reperfusion injury of the lung. J Heart Lung Transplant. 2005;24:38-45. 
41. Kaiser L, Sparks HV, Jr. Endothelial cells. Not just a cellophane wrapper. Arch 
Intern Med. 1987;147:569-573. 
42. Shah AM. Paracrine modulation of heart cell function by endothelial cells. 
Cardiovasc Res. 1996;31:847-867. 
 75
                                                                                                                                   References 
43. Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clin Sci (Lond). 
2005;109:217-226. 
44. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance 
for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol. 
2004;287:R1014-1030. 
45. Parker JC, Townsley MI. Evaluation of lung injury in rats and mice. Am J Physiol 
Lung Cell Mol Physiol. 2004;286:L231-246. 
46. Seeger W, Walmrath D, Grimminger F, Rosseau S, Schutte H, Kramer HJ, Ermert L, 
Kiss L. Adult respiratory distress syndrome: model systems using isolated perfused 
rabbit lungs. Methods Enzymol. 1994;233:549-584. 
47. Parker JC, Gillespie MN, Taylor AE, Martin SL. Capillary filtration coefficient, 
vascular resistance, and compliance in isolated mouse lungs. J Appl Physiol. 
1999;87:1421-1427. 
48. Parker JC, Prasad R, Allison RA, Wojchiechowski WV, Martin SL. Capillary 
filtration coefficients using laser densitometry and gravimetry in isolated dog lungs. 
J Appl Physiol. 1993;74:1981-1987. 
49. Seeger W, Walmrath D, Menger M, Neuhof H. Increased lung vascular permeability 
after arachidonic acid and hydrostatic challenge. J Appl Physiol. 1986;61:1781-1789. 
50. Lunde PK, Waaler BA. Transvascular fluid balance in the lung. J Physiol. 
1969;205:1-18. 
51. Taylor AE, Gaar KA. Calculation of equivalent pore radi of the pulmonary capillary 
and alveolar membrances. Rev Argent Angiol. 1969;111:25-40. 
52. Hancock BJ, Landolfo KP, Hoppensack M, Oppenheimer L. Slow phase of 
transvascular fluid flux reviewed. J Appl Physiol. 1990;69:456-464. 
53. Parker JC, Townsley MI. Physiological determinants of the pulmonary filtration 
coefficient. Am J Physiol Lung Cell Mol Physiol. 2008;295:L235-237. 
54. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling 
in hypertension: what is the clinical significance? Hypertension. 2004;44:248-252. 
 76
                                                                                                                                   References 
55. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in 
cardiovascular biology and disease. Circ Res. 2000;86:494-501. 
56. Landmesser U, Harrison DG. Oxidative stress and vascular damage in hypertension. 
Coron Artery Dis. 2001;12:455-461. 
57. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beaumont FJ, Diez J. 
Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension. 
2001;38:1395-1399. 
58. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM. 
NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 
2006;8:691-728. 
59. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J 
Med. 1985;312:159-163. 
60. Parks DA, Bulkley GB, Granger DN, Hamilton SR, McCord JM. Ischemic injury in 
the cat small intestine: role of superoxide radicals. Gastroenterology. 1982;82:9-15. 
61. Inci I, Zhai W, Arni S, Hillinger S, Vogt P, Weder W. N-acetylcysteine attenuates 
lung ischemia-reperfusion injury after lung transplantation. The Annals of Thoracic 
Surgery. 2007;84:240. 
62. Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, Keshavjee S. Report of 
the ISHLT working group on primary lung graft dysfunction Part VI: Treatment. The 
Journal of Heart and Lung Transplantation. 2005;24:1489. 
63. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: 
Animal and human studies. Circulation. 2003;108:2034-2040. 
64. Jialal I, Devaraj S. Antioxidants and atherosclerosis: Don't throw out the baby with 
the bath water. Circulation. 2003;107:926-928. 
65. Fridovich I. Superoxide anion radical (O2-.), superoxide dismutases, and related 
matters. J Biol Chem. 1997;272:18515-18517. 
 77
                                                                                                                                   References 
66. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the 
redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 
2001;30:1191-1212. 
67. Darley-Usmar V, Wiseman H, Halliwell B. Nitric oxide and oxygen radicals: a 
question of balance. FEBS Lett. 1995;369:131-135. 
68. Al-Mehdi AB, Zhao G, Dodia C, Tozawa K, Costa K, Muzykantov V, Ross C, 
Blecha F, Dinauer M, Fisher AB. Endothelial NADPH oxidase as the source of 
oxidants in lungs exposed to ischemia or high K+. Circ Res. 1998;83:730-737. 
69. Cremer J, Jurmann M, Dammenhayn L, Wahlers T, Haverich A, Borst HG. Oxygen 
free radical scavengers to prevent pulmonary reperfusion injury after heart-lung 
transplantation. J Heart Transplant. 1989;8:330-336. 
70. Babior BM. The leukocyte NADPH oxidase. Isr Med Assoc J. 2002;4:1023-1024. 
71. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular 
and cellular mechanisms. Hypertension. 2003;42:1075-1081. 
72. Fantone JC, Ward PA. Polymorphonuclear leukocyte-mediated cell and tissue injury: 
oxygen metabolites and their relations to human disease. Hum Pathol. 1985;16:973-
978. 
73. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood 
vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J 
Physiol Pharmacol. 2002;53:515-524. 
74. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, 
Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide 
production and expression of nox family proteins in human atherosclerosis. 
Circulation. 2002;105:1429-1435. 
75. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT. 
Expression of phagocyte NADPH oxidase components in human endothelial cells. 
Am J Physiol. 1996;271:H1626-1634. 
 78
                                                                                                                                   References 
76. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, 
expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 
2003;285:R277-297. 
77. Bendall JK, Rinze R, Adlam D, Tatham AL, de Bono J, Wilson N, Volpi E, Channon 
KM. Endothelial Nox2 overexpression potentiates vascular oxidative stress and 
hemodynamic response to angiotensin II: studies in endothelial-targeted Nox2 
transgenic mice. Circ Res. 2007;100:1016-1025. 
78. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: 
physiology and pathophysiology. Physiol Rev. 2007;87:245-313. 
79. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 
2004;4:181-189. 
80. Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ, Shah AM. 
Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell 
superoxide production in response to phorbol ester and tumor necrosis factor-alpha. 
Circ Res. 2002;90:143-150. 
81. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by 
angiotensin II. Role of the p47phox subunit. J Biol Chem. 2003;278:12094-12100. 
82. Cross AR, Jones OT. The effect of the inhibitor diphenylene iodonium on the 
superoxide-generating system of neutrophils. Specific labelling of a component 
polypeptide of the oxidase. Biochem J. 1986;237:111-116. 
83. Cross AR, Jones OT. Enzymic mechanisms of superoxide production. Biochim 
Biophys Acta. 1991;1057:281-298. 
84. O'Donnell BV, Tew DG, Jones OT, England PJ. Studies on the inhibitory 
mechanism of iodonium compounds with special reference to neutrophil NADPH 
oxidase. Biochem J. 1993;290 (Pt 1):41-49. 
85. Stuehr DJ, Fasehun OA, Kwon NS, Gross SS, Gonzalez JA, Levi R, Nathan CF. 
Inhibition of macrophage and endothelial cell nitric oxide synthase by 
diphenyleneiodonium and its analogs. Faseb J. 1991;5:98-103. 
 79
                                                                                                                                   References 
86. Doussiere J, Vignais PV. Diphenylene iodonium as an inhibitor of the NADPH 
oxidase complex of bovine neutrophils. Factors controlling the inhibitory potency of 
diphenylene iodonium in a cell-free system of oxidase activation. Eur J Biochem. 
1992;208:61-71. 
87. Li Y, Trush MA. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also 
potently inhibits mitochondrial reactive oxygen species production. Biochem Biophys 
Res Commun. 1998;253:295-299. 
88. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic 
targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478. 
89. Diatchuk V, Lotan O, Koshkin V, Wikstroem P, Pick E. Inhibition of NADPH 
oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related 
compounds. J Biol Chem. 1997;272:13292-13301. 
90. Cifuentes ME, Pagano PJ. Targeting reactive oxygen species in hypertension. Curr 
Opin Nephrol Hypertens. 2006;15:179-186. 
91. Lambeth JD, Krause KH, Clark RA. NOX enzymes as novel targets for drug 
development. Semin Immunopathol. 2008;30:339-363. 
92. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive 
inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic 
blood pressure in mice. Circ Res. 2001;89:408-414. 
93. Shi J, Ross CR, Leto TL, Blecha F. PR-39, a proline-rich antibacterial peptide that 
inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains 
of p47 phox. Proc Natl Acad Sci U S A. 1996;93:6014-6018. 
94. Korthuis RJ, Gute DC, Blecha F, Ross CR. PR-39, a proline/arginine-rich 
antimicrobial peptide, prevents postischemic microvascular dysfunction. Am J 
Physiol. 1999;277:H1007-1013. 
95. Chan YR, Gallo RL. PR-39, a syndecan-inducing antimicrobial peptide, binds and 
affects p130(Cas). J Biol Chem. 1998;273:28978-28985. 
 80
                                                                                                                                   References 
96. Engels F, Renirie BF, Hart BA, Labadie RP, Nijkamp FP. Effects of apocynin, a 
drug isolated from the roots of Picrorhiza kurroa, on arachidonic acid metabolism. 
FEBS Lett. 1992;305:254-256. 
97. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition 
of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted 
catechol. Am J Respir Cell Mol Biol. 1994;11:95-102. 
98. Meyer JW, Holland JA, Ziegler LM, Chang MM, Beebe G, Schmitt ME. 
Identification of a functional leukocyte-type NADPH oxidase in human endothelial 
cells:a potential atherogenic source of reactive oxygen species. Endothelium. 
1999;7:11-22. 
99. Suzuki Y, Wang W, Vu TH, Raffin TA. Effect of NADPH oxidase inhibition on 
endothelial cell ELAM-1 mRNA expression. Biochem Biophys Res Commun. 
1992;184:1339-1343. 
100. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, 
Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an 
antioxidant. Hypertension. 2008;51:211-217. 
101. Touyz RM. Apocynin, NADPH oxidase, and vascular cells: a complex matter. 
Hypertension. 2008;51:172-174. 
102. Dikalov SI, Dikalova AE, Mason RP. Noninvasive diagnostic tool for inflammation-
induced oxidative stress using electron spin resonance spectroscopy and an 
extracellular cyclic hydroxylamine. Arch Biochem Biophys. 2002;402:218-226. 
103. Dikalov S, Grigor'ev IA, Voinov M, Bassenge E. Detection of superoxide radicals 
and peroxynitrite by 1-hydroxy-4-phosphonooxy-2,2,6,6-tetramethylpiperidine: 
quantification of extracellular superoxide radicals formation. Biochem Biophys Res 
Commun. 1998;248:211-215. 
104. Dikalov S, Skatchkov M, Bassenge E. Spin trapping of superoxide radicals and 
peroxynitrite by 1-hydroxy-3-carboxy-pyrrolidine and 1-hydroxy-2,2,6, 6-
tetramethyl-4-oxo-piperidine and the stability of corresponding nitroxyl radicals 
towards biological reductants. Biochem Biophys Res Commun. 1997;231:701-704. 
 81
                                                                                                                                   References 
105. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion 
physiology. Cardiovasc Res. 2004;61:461-470. 
106. Weissmann N, Akkayagil E, Quanz K, Schermuly RT, Ghofrani HA, Fink L, Hanze 
J, Rose F, Seeger W, Grimminger F. Basic features of hypoxic pulmonary 
vasoconstriction in mice. Respir Physiol Neurobiol. 2004;139:191-202. 
107. Voswinckel R, Ziegelhoeffer T, Heil M, Kostin S, Breier G, Mehling T, Haberberger 
R, Clauss M, Gaumann A, Schaper W, Seeger W. Circulating vascular progenitor 
cells do not contribute to compensatory lung growth. Circ Res. 2003;93:372-379. 
108. Weissmann N, Kuzkaya N, Fuchs B, Tiyerili V, Schafer RU, Schutte H, Ghofrani 
HA, Schermuly RT, Schudt C, Sydykov A, Egemnazarow B, Seeger W, Grimminger 
F. Detection of reactive oxygen species in isolated, perfused lungs by electron spin 
resonance spectroscopy. Respir Res. 2005;6:86. 
109. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite 
with uric acid in the presence of ascorbate and thiols: implications for uncoupling 
endothelial nitric oxide synthase. Biochem Pharmacol. 2005;70:343-354. 
110. Schutte H, Witzenrath M, Mayer K, Weissmann N, Schell A, Rosseau S, Seeger W, 
Grimminger F. The PDE inhibitor zaprinast enhances NO-mediated protection 
against vascular leakage in reperfused lungs. Am J Physiol Lung Cell Mol Physiol. 
2000;279:L496-502. 
111. Moore TM, Khimenko PL, Taylor AE. Endothelial damage caused by ischemia and 
reperfusion and different ventilatory strategies in the lung. Chin J Physiol. 
1996;39:65-81. 
112. Dodd OJ, Pearse DB. Effect of the NADPH oxidase inhibitor apocynin on ischemia-
reperfusion lung injury. Am J Physiol Heart Circ Physiol. 2000;279:H303-312. 
113. Dodd-o JM, Hristopoulos ML, Welsh-Servinsky LE, Tankersley CG, Pearse DB. 
Strain-specific differences in sensitivity to ischemia-reperfusion lung injury in mice. 
J Appl Physiol. 2006;100:1590-1595. 
 82
                                                                                                                                   References 
114. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox 
containing NADPH oxidase selectively expressed in endothelial cells is a major 
source of oxygen radical generation in the arterial wall. Circ Res. 2000;87:26-32. 
115. Haque MZ, Majid DS. Assessment of renal functional phenotype in mice lacking 
gp91PHOX subunit of NAD(P)H oxidase. Hypertension. 2004;43:335-340. 
116. Amieux PS, Cummings DE, Motamed K, Brandon EP, Wailes LA, Le K, Idzerda 
RL, McKnight GS. Compensatory regulation of RIalpha protein levels in protein 
kinase A mutant mice. J Biol Chem. 1997;272:3993-3998. 
117. Shiloh MU, MacMicking JD, Nicholson S, Brause JE, Potter S, Marino M, Fang F, 
Dinauer M, Nathan C. Phenotype of mice and macrophages deficient in both 
phagocyte oxidase and inducible nitric oxide synthase. Immunity. 1999;10:29-38. 
118. Pearse DB, Becker PM. Effect of time and vascular pressure on permeability and 
cyclic nucleotides in ischemic lungs. Am J Physiol Heart Circ Physiol. 
2000;279:H2077-2084. 
119. Pinsky DJ, Naka Y, Chowdhury NC, Liao H, Oz MC, Michler RE, Kubaszewski E, 
Malinski T, Stern DM. The nitric oxide/cyclic GMP pathway in organ 
transplantation: critical role in successful lung preservation. Proc Natl Acad Sci U S 
A. 1994;91:12086-12090. 
120. Vazquez-Torres A, Jones-Carson J, Mastroeni P, Ischiropoulos H, Fang FC. 
Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide 
synthase in experimental salmonellosis. I. Effects on microbial killing by activated 
peritoneal macrophages in vitro. J Exp Med. 2000;192:227-236. 
121. Cale AR, Katzmann JA, Tazelaar HD, Miller VM, McGregor CG. Activation of 
polymorphonuclear leukocyte oxygen radical production during acute lung rejection 
in dogs: inhibition by an antiadhesion molecule monoclonal antibody. J Heart Lung 
Transplant. 1993;12:948-954; discussion 955. 
122. Klausner JM, Anner H, Paterson IS, Kobzik L, Valeri CR, Shepro D, Hechtman HB. 
Lower torso ischemia-induced lung injury is leukocyte dependent. Ann Surg. 
1988;208:761-767. 
 83
                                                                                                                                   References 
123. Adkins WK, Taylor AE. Role of xanthine oxidase and neutrophils in ischemia-
reperfusion injury in rabbit lung. J Appl Physiol. 1990;69:2012-2018. 
124. Bishop MJ, Kowalski TF, Guidotti SM, Harlan JM. Antibody against neutrophil 
adhesion improves reperfusion and limits alveolar infiltrate following unilateral 
pulmonary artery occlusion. J Surg Res. 1992;52:199-204. 
125. Seibert AF, Haynes J, Taylor A. Ischemia-reperfusion injury in the isolated rat lung. 
Role of flow and endogenous leukocytes. Am Rev Respir Dis. 1993;147:270-275. 
126. Ermert L, Seeger W, Duncker HR. Computer-assisted morphometry of the 
intracapillary leukocyte pool in the rabbit lung. Cell Tissue Res. 1993;271:469-476. 
127. Martin BA, Wiggs BR, Lee S, Hogg JC. Regional differences in neutrophil 
margination in dog lungs. J Appl Physiol. 1987;63:1253-1261. 
128. Gee MH, Albertine KH. Neutrophil-endothelial cell interactions in the lung. Annu 
Rev Physiol. 1993;55:227-248. 
129. Ermert L, Duncker HR, Rosseau S, Schutte H, Seeger W. Morphometric analysis of 
pulmonary intracapillary leukocyte pools in ex vivo-perfused rabbit lungs. Am J 
Physiol. 1994;267:L64-70. 
130. Bayraktutan U, Draper N, Lang D, Shah AM. Expression of functional neutrophil-
type NADPH oxidase in cultured rat coronary microvascular endothelial cells. 
Cardiovasc Res. 1998;38:256-262. 
131. Bayraktutan U, Blayney L, Shah AM. Molecular characterization and localization of 
the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. 
Arterioscler Thromb Vasc Biol. 2000;20:1903-1911. 
132. Yang Z, Sharma AK, Marshall M, Kron IL, Laubach VE. NADPH oxidase in bone 
marrow-derived cells mediates pulmonary ischemia-reperfusion injury. Am J Respir 
Cell Mol Biol. 2008. 
133. Yao H, Edirisinghe I, Yang SR, Rajendrasozhan S, Kode A, Caito S, Adenuga D, 
Rahman I. Genetic ablation of NADPH oxidase enhances susceptibility to cigarette 
smoke-induced lung inflammation and emphysema in mice. Am J Pathol. 
2008;172:1222-1237. 
 84
                                                                                                                                   References 
134. Schaper M, Leib SL, Meli DN, Brandes RP, Tauber MG, Christen S. Differential 
effect of p47phox and gp91phox deficiency on the course of Pneumococcal 
Meningitis. Infect Immun. 2003;71:4087-4092. 
135. Millar TM, Phan V, Tibbles LA. ROS generation in endothelial hypoxia and 
reoxygenation stimulates MAP kinase signaling and kinase-dependent neutrophil 
recruitment. Free Radic Biol Med. 2007;42:1165-1177. 
136. Lu YT, Hellewell PG, Evans TW. Ischemia-reperfusion lung injury: contribution of 
ischemia, neutrophils, and hydrostatic pressure. Am J Physiol. 1997;273:L46-54. 
137. Adding LC, Bannenberg GL, Gustafsson LE. Basic experimental studies and clinical 
aspects of gadolinium salts and chelates. Cardiovasc Drug Rev. 2001;19:41-56. 
138. Veldhuizen RA, Lee J, Sandler D, Hull W, Whitsett JA, Lewis J, Possmayer F, 
Novick RJ. Alterations in pulmonary surfactant composition and activity after 
experimental lung transplantation. Am Rev Respir Dis. 1993;148:208-215. 
139. Hausen B, Rohde R, Hewitt CW, Schroeder F, Beuke M, Ramsamooj R, Schafers 
HJ, Borst HG. Exogenous surfactant treatment before and after sixteen hours of 
ischemia in experimental lung transplantation. J Thorac Cardiovasc Surg. 
1997;113:1050-1058. 
140. Erasmus ME, Petersen AH, Hofstede G, Haagsman HP, Bambang Oetomo S, Prop J. 
Surfactant treatment before reperfusion improves the immediate function of lung 
transplants in rats. Am J Respir Crit Care Med. 1996;153:665-670. 
141. van der Kaaij NP, Haitsma JJ, Kluin J, Lambrecht BN, Lachmann B, de Bruin RW, 
Bogers AJ. Surfactant pretreatment ameliorates ischemia-reperfusion injury of the 
lung. Eur J Cardiothorac Surg. 2005;27:774-782. 
142. van Putte BP, Cobelens PM, van der Kaaij N, Lachmann B, Kavelaars A, Heijnen 
CJ, Kesecioglu J. Exogenous surfactant attenuation of ischemia-reperfusion injury in 
the lung through alteration of inflammatory and apoptotic factors. J Thorac 
Cardiovasc Surg. 2009;137:824-828. 
 85
                                                                                                                                   References 
143. Forbes A, Pickell M, Foroughian M, Yao LJ, Lewis J, Veldhuizen R. Alveolar 
macrophage depletion is associated with increased surfactant pool sizes in adult rats. 
J Appl Physiol. 2007;103:637-645. 
144. Baritussio A, Alberti A, Armanini D, Meloni F, Bruttomesso D. Different pathways 
of degradation of SP-A and saturated phosphatidylcholine by alveolar macrophages. 
Am J Physiol Lung Cell Mol Physiol. 2000;279:L91-99. 
145. Kassim SY, Fu X, Liles WC, Shapiro SD, Parks WC, Heinecke JW. NADPH 
oxidase restrains the matrix metalloproteinase activity of macrophages. J Biol Chem. 
2005;280:30201-30205. 
146. Wang LF, Mehta S, Weicker S, Scott JA, Joseph M, Razavi HM, McCormack DG. 
Relative contribution of hemopoietic and pulmonary parenchymal cells to lung 
inducible nitric oxide synthase (iNOS) activity in murine endotoxemia. Biochem 
Biophys Res Commun. 2001;283:694-699. 
147. Matute-Bello G, Lee JS, Frevert CW, Liles WC, Sutlief S, Ballman K, Wong V, Selk 
A, Martin TR. Optimal timing to repopulation of resident alveolar macrophages with 
donor cells following total body irradiation and bone marrow transplantation in mice. 
J Immunol Methods. 2004;292:25-34. 
148. Sohn HY, Krotz F, Gloe T, Keller M, Theisen K, Klauss V, Pohl U. Differential 
regulation of xanthine and NAD(P)H oxidase by hypoxia in human umbilical vein 
endothelial cells. Role of nitric oxide and adenosine. Cardiovasc Res. 2003;58:638-
646. 
149. Sohn HY, Keller M, Gloe T, Morawietz H, Rueckschloss U, Pohl U. The small G-
protein Rac mediates depolarization-induced superoxide formation in human 
endothelial cells. J Biol Chem. 2000;275:18745-18750. 
150. Manevich Y, Al-Mehdi A, Muzykantov V, Fisher AB. Oxidative burst and NO 
generation as initial response to ischemia in flow-adapted endothelial cells. Am J 
Physiol Heart Circ Physiol. 2001;280:H2126-2135. 
151. Wei Z, Costa K, Al-Mehdi AB, Dodia C, Muzykantov V, Fisher AB. Simulated 
ischemia in flow-adapted endothelial cells leads to generation of reactive oxygen 
species and cell signaling. Circ Res. 1999;85:682-689. 
 86
                                                                                                                                   References 
152. Johnson DK, Schillinger KJ, Kwait DM, Hughes CV, McNamara EJ, Ishmael F, 
O'Donnell RW, Chang MM, Hogg MG, Dordick JS, Santhanam L, Ziegler LM, 
Holland JA. Inhibition of NADPH oxidase activation in endothelial cells by ortho-
methoxy-substituted catechols. Endothelium. 2002;9:191-203. 
153. Astern JM, Pendergraft WF, 3rd, Falk RJ, Jennette JC, Schmaier AH, Mahdi F, 
Preston GA. Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 
and modulates bradykinin production by the plasma Kallikrein-Kinin system. Am J 
Pathol. 2007;171:349-360. 
154. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites 
of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul 
Integr Comp Physiol. 2004;286:R431-444. 
 
 
 87
                                                                                                                   List of abbreviations 
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A     adenine 
AEBSF   4-(2-Aminoethyl)benzenesulfonylfluoride 
ATP     adenosine triphosphate 
bp     base pair 
C     cytosine 
CO2     carbon dioxide 
CPH     1-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine 
DNA     deoxyribonucleic acid 
dNTP    2’-deoxynucleotide-5’-triphosphate 
DPI     diphenylene iodonium 
DTPA    diethylenetriamine-pentaacetic acid 
EDTA    ethylenediaminetetraacetic acid 
ESR     electron spin resonance 
G     guanine 
h     hour 
HAES    hydroxyethyl starch 
HRB     Hepes-Ringer buffer 
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Kfc     capillary filtration coefficient 
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